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ABSTRACT
During tumor progression, cancer cells undergo a number of alterations to evade 
tumor inhibitory mechanisms, proliferate, invade surrounding tissues and metastasize to 
distant sites. These properties reflect changes in their cell signaling pathways that, in 
normal cells, control aberrant cell proliferation, motility, and survival. Over the past few 
decades, hyperactive Wnt/β-catenin signaling has been linked to the formation of 
multiple cancers, including malignant ovarian cancer, making identification of molecules 
regulating Wnt/β-catenin signaling crucial to the development of early detection methods 
and cancer treatment strategies. Proteoglycans, which regulate transmission of cellular 
signals, are implicated in the pathophysiology of diseases, including cancer, where 
signals and tissue interactions malfunction. These cell surface molecules consist of a core 
protein decorated extracellularly with covalently linked heparan sulfate (HS), chondroitin 
sulfate (CS), dermatan sulfate and/or keratan sulfate glycosaminoglycan (GAG) chain 
modifications. A small group of proteoglycans that contain the two most common GAG 
chain attachments, HS and CS chains, span the cell membrane to regulate signal 
transduction and are hereby referred to as dually modified transmembrane proteoglycans 
(DMTPs).  Two examples of DMTPs are betaglycan (TβRIII) and syndecan-1 (SDC1). 
These DMTPs play important roles in modulating key cell signaling pathways to affect 
epithelial cell biology and cancer progression. The overall goal of my dissertation 
research was to determine the impact of betaglycan, a well-established TGFβ co-receptor, 
on Wnt/β-catenin signaling. To this end, my work has revealed new roles for betaglycan 
vii	
in Wnt signaling. Specifically, depending on its GAG chain modification, betaglycan can 
either enhance or suppress canonical Wnt/β-catenin signaling. My findings implicate 
interactions between Wnt and betaglycan’s HS chains in inhibiting Wnt signaling, likely 
via Wnt sequestration, while the CS GAG chains on betaglycan promote Wnt signaling. 
My studies reveal a novel, dual role for TβRIII/betaglycan and define a key requirement 
for the balance between CS and HS chains in dictating ligand responses. Ultimately, my 
findings will help unravel the complex roles that DMTPs and their GAG chains play in 
regulating ligand availability and cell signal transduction during disease progression. 
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Transmembrane proteoglycans (TP) are members of the heparan sulfate 
proteoglycan (HSPG) family whose core domains span the cell membrane to modulate a 
multitude of intracellular and extracellular activities(1-10). TP extracellular domains 
(ECD) contain covalently attached glycosaminoglycan (GAG) chain modifications that 
include heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate and/or keratan 
sulfate, with HS and CS chains being the most common(2). As members of the GAG 
family, HS and CS chains are characterized by repeating disaccharide units containing 
glucuronic acid and either N-acetylgalactosamine for HS or N-acetylglucosamine for 
CS(1). Of the known human transmembrane proteoglycans, only a few can present both 
HS and CS chains and are referred to here as dually modified transmembrane 
proteoglycans (DMTP). Human DMTP members include the Type III Transforming 
Growth Factor β Receptor/Betaglycan, Syndecans-1 and -3, CD44 and Neuropilin-1.  
Syndecan-3 (SDC3), similar to betaglycan and syndecan-1 (SDC1), contains both CS and 
HS chains but is found almost exclusively in neuronal and musculoskeletal tissue(11) 
with defined roles in skeletogenesis(12) and neurite growth(13). Unlike SDC3, CD44 is 
expressed in many different cell types(14) and in various isoforms, which can exhibit HS 
and/or CS chains depending on the splice variant(2,15-18). In epithelial cells, the primary 
form of CD44, known as CD44E or CD44v8-10, lacks the variable region (exon v3) 
required for HS chain attachment and therefore can only express CS chains(14,18-21). 
Neuropilin-1 (NRP1), which is prominent in neuronal and endothelial cells, has clearly 
outlined roles in axonal growth/guidance as well as physiological and pathological 
angiogenesis(22-24). Since NRP1 only contains one serine residue (Ser612) for GAG 
chain attachment, it can only exist as a HS proteoglycan or a CS proteoglycan but not as a 
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hybrid of the two(24-27). DMTPs are present in both membrane-bound and/or 
shed/soluble forms with these forms able to impact cell behavior by either mimicking or 
opposing each other’s cellular functions. Contributions from the core domain’s 
scaffolding properties can also influence GAG chain-ligand binding(7), highlighting the 
importance of the HSPGs’ core domain in delineating roles for GAG chains. 
Consequently, shed/soluble DMTPs and their attached GAG chains can affect ligand 
availability, downstream signaling and promote interactions between GAG chains, 
ligands and the extracellular environment(28).  
The background summarizes regulatory roles for both betaglycan and SDC1 in 
growth factor signaling with the dissertation work focused primarily on betaglycan in 
Wnt signaling. I emphasize the underappreciated mutual dependence of HSPGs’ GAG 
chains and core protein and their impact in disease, with a focus on cancer progression. 
Finally, I provide comprehensive information on these DMTPs for the future 
development of therapeutic techniques to modulate growth factor/ligand availability and 
thus control downstream cell signaling pathways involved in human disease.   
1.1 DMTP Structure and Features 
1.1.i. Core Structure 
Both SDC1 and betaglycan are proteoglycans containing a large ECD, a 
transmembrane domain and a short cytoplasmic domain (~200 amino acids or less) that 
lacks intrinsic kinase activity. Betaglycan’s ECD contains a zona pellucida domain (ZP1 
and ZP2, Figure 1.1), which is important for protein polymerization and protein-protein 
interactions(29). Specifically, betaglycan’s ZP domain contains two distinct 
Transforming Growth Factor β (TGF-β) binding sites: one in the membrane-distal region 
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(ZP1)(Figure 1.1 and (30)) and one in the membrane-proximal ZP region (ZP2)(Figure 
1.1 and (31)). TGF-β ligands TGF-β1/2/3, Bone Morphogenetic Proteins (BMPs) 2/4/7 
and Growth Differentiation Factor 5 (GDF-5) can bind both regions while the TGF-β 
member Inhibin only binds the ZP region (ZP2)(32,33). Unlike betaglycan, little is 
known about SDC1’s ectodomain core independent of its GAG chain functions. SDC1’s 
235 amino acid(34) extracellular core, however, does support fibroblast cell 
adhesion(35), interacts with integrins αvβ3 and αvβ5 during angiogenesis and αvβ1 
integrin during re-epithelialization of lung tissue(36-40).   
The short cytoplasmic domains of DMTPs are serine/threonine rich, frequently 
phosphorylated and contain a PDZ (Postsynaptic Density-95/Disc large protein/Zonula 
occludens-1) binding motif at the extreme carboxy terminus. These cytoplasmic regions 
commonly interact with scaffolding proteins to control DMTP internalization and cell 
signaling (Figure 1.1 and (2,34,41,42)). Betaglycan’s short cytoplasmic domain, through 
its Class I PDZ binding motif, binds the scaffolding protein GAIP-interacting protein C 
terminus (GIPC) to modulate TGF-β signaling (43).  
Additionally, the Type II TGF-β Receptor (TβRII) can phosphorylate 
betaglycan’s cytoplasmic domain at Thr841 to promote β-arrestin2-betaglycan interactions 
and receptor internalization (44). SDC1’s cytoplasmic domain is divided into two 
conserved regions, C1 and C2 (Figure 1.1), which are common regions between all 
syndecans, and a central variable region (V, Figure 1.1), which confers specific properties 
on each syndecan (Figure 1.1 and (45)). SDC1’s V domain regulates cell spreading and 
actin cytoskeleton assembly(46) while its C1 domain, adjacent to the membrane, 
participates in SDC1 dimerization and intracellular protein binding(47). The conserved 
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C2 carboxyl-terminal tetrapeptide sequence can bind PDZ-domain-containing 
proteins(41,42), which may function as membrane scaffold proteins that recruit signaling 
and cytoskeletal proteins to the plasma membrane. Contributions from the core domain’s 
scaffolding properties are likely to influence GAG chain-ligand binding by either 
immobilizing the chains to specific sites within the plasma membrane(7) or by altering 
the internalization of ligands bound to GAG chains (48). Additionally, the position of the 
GAG chains on the core protein (plasma membrane distal or proximal) could impact 
GAG chain association with receptors and subsequent DMTP function. 
1.1.ii. GAG Chain Structure 
On the extracellular core of DMTPs are sites for linear polysaccharide GAG chain 
attachments (Figure 1.1 and (1,2,30,34,49)). Synthesis of DMTP GAG chains begins with 
covalent attachment of a linkage tetrasaccharide, glucuronic acid-galactose-galactose-
xylose (GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-), to a serine hydroxyl group on the core 
protein followed by addition of repeating disaccharide regions composed of hexosamine 
and hexuronic acids (Figure 1.1 and (49)). The repeating disaccharide units distinguish 
HS chains from CS chains. During initial synthesis of HS chains, a N-acetylglucosamine 
(GlcNac) is attached to the linkage tetrasaccharide by α1,4-N-
acetylglucosaminyltransferase-I (α4GlcNAcT-I). On the other hand, synthesis of the CS 
chains occurs when β1,4-N-acetylgalactosaminyltransferase-I (β4GalNAcT-I) attaches a 
N-acetylgalactosamine disaccharide to the linkage tetrasaccharide(49). The first 
hexosamine residue thus determines which chain is made (HS or CS). After attachment of 
this fifth saccharide, the chondroitin synthase family (for CS chains) or exostosins (for 
HS chains) attach the remaining disaccharide units(49). HS chains can then be selectively 
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sulfated at the N, 3-O and 6-O positions of glucosamine and the 2-O position of uronic 
acid residues by sulfotransferases(50) while sulfate groups on CS chains are added at C-4 
and/or C-6 of N-acetyl-galactosamine and/or C-2 of glucuronic acid(51). In vertebrates, 
SDC1 is one of four syndecan family members and is the primary syndecan expressed in 
epithelial cells(52). As a “full-time” proteoglycan (no GAG-less form in vivo), SDC1’s 
ECD contains three attachments sites for HS chains (Ser37, Ser45 and Ser47) and two sites 
for CS chain attachment (Ser210 and Ser220)(Figure 1.1 and (34,53,54)). While SDC1 is an 
obligate or “full-time” DMTP, betaglycan is commonly referred to as a “part-time” 
proteoglycan since it can be expressed with or without GAG chains(1,2,49,55) in vivo. 
CS chains attach to betaglycan’s 100 kDa protein core primarily at Ser545. CS chains can 
also attach at Ser534, but HS chains usually predominate at this site (Figure 1.1 and 
(30,49,56)). Both alterations in core protein expression and GAG chain density and/or 
composition (HS vs. CS) can impact DMTP functions. 
1.1.iii. Shedding and Intracellular Domain (ICD) Cleavage 
Several DMTP functions can be attributed to ectodomain shedding which leads to 
DMTP expression in both membrane-bound and shed/soluble forms. Both forms can 
impact whether GAG chains are anchored to the membrane or present as soluble GAGs 
in the extracellular matrix (ECM). Cleavage occurs near the transmembrane domain to 
release a soluble ectodomain containing GAG chains (Figure 1.1). This ectodomain 
shedding is highly regulated by the enzymatic activity of several proteases(2,39,57-61) 
including matrix metalloproteinases (MMP) and metalloprotease disintegrins. Enzymatic 
activity by pervanadate, a general tyrosine phosphatase inhibitor, stimulates cleavage of 
both SDC1(62) and betaglycan(59). Sheddases Membrane type MMP-7(63,64), 
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matrilysin(65), MMP-9(66) and MMP-1(60) cleave SDC1’s ECD. Intriguingly, shedding 
for SDC1 has also been shown to be regulated by intracellular interaction of the small 
GTPase Rab5 with SDC1’s intracellular domain as Rab5’s dissociation from SDC1’s 
cytoplasmic domain triggers SDC1 ectodomain shedding at the cell surface(63). It is 
postulated that activated GTP-Rab5 dissociates from SDC1’s cytoplasmic domain, 
associates with β1 integrin and stimulates the internalization of β1 integrin and 
dissociation of β1 integrin from SDC1. This cascade of events exposes SDC1’s ECD 
cleavage site to sheddases(63).Whether such intracellular control of betaglycan shedding 
exists has not been tested.  However, the ECD of betaglycan is cleaved by MMP-1 and -
3(59). Both SDC1 and betaglycan’s transmembrane/cytoplasmic fragments can be 
cleaved by γ-secretase to release both DMTPs’ cytoplasmic domains intracellularly 
(Figure 1.1 and (67,68)). Functions for these cytoplasmic domains are reviewed in 
(67,68).  
Expression of different GAG chains on membrane bound DMTPs can impact 
soluble DMTP (sDMTP) pools, as observed with membrane bound SDC1’s HS chains, 
where higher membrane bound HS modified SDC1 leads to lower SDC1 shedding(69). 
Altering the balance of membrane bound versus soluble DMTPs could, in effect, impact 
cell signaling by altering ligand interactions with sDMTPs’ ECD/GAG chains (See 
Chapters 2-4). In the cell media, for example, increased levels of sDMTPs containing HS 
chains exclusively could suppress signaling as they may act as ligand traps capable of 
reducing ligand availability to the membrane-bound cognate receptors. Cleaved DMTP 
ectodomains containing CS chains could prevent ligand aggregation in the cell media, 
thereby facilitating ligand-receptor interaction and increasing cancer cell signaling. Given 
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the current impact of DMTPs in regulating cell signaling, as outlined in Chapters 2-4, an 
in-depth analysis of the GAG chain composition on membrane-bound and sDMTPs may 
clarify roles for DMTPs and their GAG chains in modulating growth factor signaling and 
cell biology. 
1.2. DMTPs in Development 
SDC1 is expressed during development to modulate tissue morphogenesis as well 
as during wound healing, with several of its developmental functions mediated by its 
GAG chains’ interactions with a number of extracellular adhesion proteins and growth 
factors(46,52,70). SDC1 interaction with laminin, for example, is completely dependent 
on both its HS and CS chains and leads to increased cell adhesion to the basement 
membrane(71). However, SDC1’s CS chains promote Slit signaling to drive axon and 
myotube guidance when bound to the core protein(28,72), suggesting differential roles 
for the independent GAG chains. Betaglycan’s significance in development is 
underscored by the observed embryo lethality in betaglycan knockout mice after 13.5 
days(73,74). This lethality is partly due to significant impairment of coronary 
vasculogenesis in betaglycan-null mice, demonstrating a requirement for betaglycan in 
coronary vessel development and embryonic viability(74). Additionally, betaglycan-
specific antisera inhibits mesenchyme formation and endothelial cell migration in the 
atrioventricular (AV) cushion, where cardiac endothelial cells lining the lumen of the AV 
cushion undergo epithelial-mesenchymal transformation (EMT) to participate in valve 
and membranous septa formation(75-77). Moreover, betaglycan overexpression in non-
transforming ventricular endothelial cells confers transformation in response to TGF-β2, 
suggesting betaglycan promotes heart cell transformation via TGF-β signaling(76). As 
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part of the adaptive immune response, T-cell receptors (TCRs), which are expressed on T 
lymphocytes, recognize antigens associated with molecules of the major 
histocompatibility complex(78). In both lymphoid and stromal cells of the thymus, 
betaglycan has been shown to promote T-cell development by protecting thymocytes 
from apoptosis(79). Individual functions for betaglycan’s HS and CS chains during 
development are still under investigation. 
1.3. DMTPs in Disease 
Over the past few decades, an increasing body of evidence suggests that HS and 
CS chains heavily influence cell biology and cancer progression(80). GAG chains, which 
are present at the cell surface of almost all tumor cells(80), can regulate growth factor 
signaling, tumor cell survival, angiogenesis, growth, invasion and metastasis(80). HSPGs 
can exhibit both pro-tumorigenic(3-6) and anti-tumorigenic effects depending on their 
GAG modifications(7-10). In addition to cancer, changes in HSPG expression/function 
are also observed in other human diseases, including arthritis, inflammation(3), 
Alzheimer’s/dementia(81), osteoporosis(82), fibrosis(83) and ischemic heart disease(84). 
Furthermore, HSPGs have been shown to alter wound healing and matrix remodeling, 
outcomes that can impact a broad range of pathologies(3,73,84,85), making our 
understanding of HSPG/GAG chain roles in the context of the cellular environment 
critical. Since much of the research emphasis has been placed on HSPG/GAG chain roles 
in cancer (>8% of all PubMed articles), my dissertation work will focus on summarizing 




1.3.i. DMTPs in Cancer 
Both SDC1 and betaglycan have established roles in regulating tumor progression 
with specific roles in apoptosis, adhesion, angiogenesis, proliferation, migration, invasion 
and metastasis in vitro and in vivo(2,9,39,52,86-96). The membrane-bound form of SDC1 
is capable of suppressing apoptosis as SDC1 knockdown in myeloma cells induce growth 
arrest and apoptosis(4). Other reports, however, indicate that recombinant human SDC1 
ectodomains induce apoptosis in breast cancer cells(8). Whether differential GAG 
modifications in the recombinant SDC1 ectodomains versus SDC1 in myeloma account 
for the differences observed is unclear. Moreover, while increased SDC1 levels correlate 
with a more favorable prognosis in mesothelioma, head and neck, pancreatic, lung and 
invasive breast cancers(2,3,39,97,98), both tumor promoting and tumor suppressing 
effects have been noted in colorectal and prostate cancers(39). These seemingly 
contradictory functions for SDC1 emphasize the variability of DMTP roles in cancer. 
Similarly, in the case of betaglycan, loss or reduced expression has been demonstrated in 
tumors(86-88,91,99). In particular, betaglycan expression has been shown to be a strong 
predictor of overall and recurrence-free patient-survival in certain cancers, such as breast 
cancer and neuroblastoma(86,90,100). Although betaglycan expression is commonly lost 
in most tumor types, acting primarily as a tumor suppressor(2,86-88,90,100), betaglycan 
expression has been shown to be elevated in colon cancer, a subset of triple negative 
breast cancers and high-grade lymphomas, indicating context dependent functions for 
betaglycan(5,6,101). Whether or not betaglycan’s differential role in cancer can be 
attributed to its HS and CS chain functions remains to be determined.  
In addition to controlling cell signaling in an autocrine fashion, sSDC1 can also 
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deliver growth factors in a paracrine manner to neighboring cells in the environment. 
sSDC1 from multiple myeloma cells, for example, transports hepatocyte growth factor 
(HGF) to bone marrow stromal cells to regulate gene expression(39,102). These 
HGF/sSDC1 interactions in the ECM likely cooperate with already established roles for 
membrane SDC1 in promoting myeloma cell growth, survival and spread through HS 
chains interactions with HGF(3). Betaglycan levels in the tumor stroma may vary 
depending on the tumor type. For instance, betaglycan expression is significantly higher 
in the stroma of early-stage, stroma-rich neuroblastomas(100), yet is down regulated in 
the tumor stroma of breast tumors(103). In neuroblastoma, increased stromal expression 
confers a significant survival advantage as patients with increased stromal betaglycan 
exhibited significantly higher event-free survival due, in part, to increased Fibroblast 
Growth Factor (FGF) signaling and differentiation(100). Contrastingly, in breast tumor 
stroma, decreased betaglycan mRNA and protein expression is linked to poorer patient 
outcome(103), supporting betaglycan’s contextual roles in cancer. Whether stromal cells 
can take up sBetaglycan from tumor cells to impact gene expression, like in the case of 
sSDC1, has not been determined. Taken together, these data suggest that DMTPs can 
have important effects on cancer progression as potent regulators of tumor stromal 
interactions mediated partly through their GAG chains.  
In the tumor environment, cancer cells can subvert the host immune system with 
mechanisms similar to those they use to evade immunotherapeutic strategies(104-106). 
Additionally, effector cell dysfunction and an increased number of regulatory/suppressor 
T-cells in cancer patients may further limit the efficacy of immunotherapeutic 
approaches(107). In murine and human lymphocyte subpopulations, betaglycan is 
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significantly and preferentially expressed on naïve and central memory T-cells and is 
upregulated upon TCR stimulation. Treating cells with sBetaglycan decreased 
regulatory/suppressor FoxP3+ T-cell generation, in a TGF-β-dependent manner, 
suggesting a promoter role for betaglycan in T-cell tolerance and immune responses(78). 
In both murine breast cancer and melanoma, progressive loss of betaglycan expression 
generates an immunotolerant tumor microenvironment whereby TGF-β signaling is 
enhanced and upregulates both immunoregulatory enzyme indoleamine 2,3-dioxygenase 
in plasmacytoid dendritic cells (DCs) and the CCL22 chemokine in myeloid DCs(104). 
This mechanism, coupled with the elevated TGF-β levels, creates an immunotolerant 
environment and may facilitate tumor progression and metastasis(104). Contrary to 
betaglycan’s ability to increase tumor sensitivity to immune defenses, SDC1 appears to 
aid in cancer’s subversion of the host immune system. For example, myeloma cells 
coated with anti-SDC1 antibodies displayed enhanced cross-presentation of tumor-
derived cellular antigens and generated tumor specific–killer T cells by DCs(108), 
suggesting an immunosuppressive role for SDC1. Additionally, anti-SDC1 immunotoxin 
(IT, B-B4-SO6), in combination with the chemotherapeutic drug doxorubicin, led to 
increased cell death in doxorubicin-sensitive multiple myeloma cells(109), further 
supporting SDC1’s tumor promoter role. An in-depth analysis of DMTPs and their GAG 
chains in modulating interactions between the immune system and malignant cells is 
warranted as it could strongly augment the design of clinically more efficient 
immunotherapy strategies.  
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Figure 1.1. Structure and features of DMTPs betaglycan and SDC1. (A) Structures of 
DMTP CS (top) and HS (lower) glycosaminoglycan (GAG) chains. Both GAG chains 
share a common linkage tetrasaccharide covalently attached to a serine hydroxyl group 
on the DMTP core protein. These serine residues have an adjacent glycine residue on the 
carboxy-terminal side and usually lie within an area rich in acidic residues. (B) 
Betaglycan’s core protein contains two ZP domains in its ECD for ligand binding and 
both DMTPs contain a small cytoplasmic domain, which can be cleaved by γ-secretase to 
release the cytoplasmic fragment. A PDZ motif in betaglycan’s cytoplasmic domain is 
frequently phosphorylated and regulates betaglycan cell surface expression and 
intracellular protein interactions. SDC1’s cytoplasmic domain is divided into two 
conserved regions and a variable region, which are responsible for intracellular protein 
binding. SDC1 can also interact with proteins containing a PDZ motif. Betaglycan and 
SDC1 both undergo ectodomain shedding by MMPs to release (C) soluble forms of each 
receptor, which can both bind growth factors and modulate their activity. Abbreviations: 
C1: Conserved Domain 1, C2: Conserved Domain 2, MMP: Matrix Metalloproteinases, 
PDZ: Postsynaptic Density-95/Disc large protein/Zonula occludens-1, sBetaglycan: 
Soluble/shed betaglycan, sSDC1: Soluble/shed SDC1, V: Variable Domain, ZP: Zona 
Pellucida, HS: Heparan Sulfate, CS: Chondroitin Sulfate.
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CHAPTER 2 
WNT SIGNALING REGULATION BY BETAGLYCAN 2
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K., and Mythreye, K. (2016) Altering the Proteoglycan State of Transforming Growth 
Factor beta Type III Receptor (TbetaRIII)/Betaglycan Modulates Canonical Wnt/beta-
Catenin Signaling. The Journal of biological chemistry 291, 25716-25728. 
Reprinted here with permission of publisher. 
 15 
2.1. Introduction 
Wnt glycoproteins regulate three distinct Wnt signaling pathways to mediate cell 
fate, proliferation and apoptosis as well as cancer initiation and progression in multiple 
cancers, including ovarian (110-118). Activation of the canonical Wnt/β-catenin pathway 
begins with binding of Wnt to its cell surface receptors, Frizzled and low-density 
lipoprotein receptor (LDLR)-related proteins LRP5/6, followed by phosphorylation of 
LRP5/6, recruitment of Dishevelled (Dsh) to the plasma membrane to interact with 
Frizzled and stabilization of cytosolic β-catenin (119). Axin interaction with 
phosphorylated LRP5/6 and Dsh leads to inactivation of the β-catenin destruction 
complex, accumulation of β-catenin and translocation to the nucleus to regulate Wnt 
target genes by binding to TCF/LEF transcription factors (119,120). The Wnt signaling 
cascade is controlled, in part, by transmembrane proteoglycans, which interact with Wnt 
signaling components and can either stimulate or inhibit signaling activity.  For instance, 
the HSPGs Glypican-3 and Syndecan-1 stimulate canonical Wnt signaling (121,122) 
while others, including Glypican-1 and Glypican-6 suppress Wnt signaling (122,123).  
The Type III TGF-β receptor (TβRIII)/Betaglycan is a transmembrane 
proteoglycan with loss resulting in embryonic lethality in mice (73). Beyond its roles in 
regulating TGF-β signaling, betaglycan also controls several other pathways to inhibit 
cell migration, invasion, cell growth and angiogenesis in both in vitro and in vivo cancer 
models (2,86-91) and regulating differentiation through FGF2 signaling (9). 
Mechanistically, betaglycan regulates these pathways by either altering the actin 
cytoskeleton, via betaglycan/β-arrestin2 cytoplasmic interactions (124), or through GAG 
chain interactions with FGF2 (9). Overall, betaglycan also acts as a tumor suppressor in 
prostate (89), lung (125), pancreatic (88) and breast cancer (86,90,93,95) but has been 
shown to promote metastasis in specific mesenchymal-stem like breast cancers (6)  
indicating complex roles for betaglycan in cancer. 
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Although betaglycan’s core can bind TGF-β superfamily members with high 
affinity (30,44,91) the extracellular domain also contains two sites of heparan and 
chondroitin sulfate GAG chain modifications resulting in betaglycan existing in multiple 
forms in vivo (30,126,127). Given that Wnt glycoproteins have a high affinity for both 
heparan and chondroitin GAG chains on proteoglycans (50,122), we initiated studies to 
determine the possible role of betaglycan on canonical Wnt3a signaling.   
We find, using both cancer and normal epithelial cells and a combination of loss 
and gain-of-function approaches, that betaglycan suppresses Wnt3a signaling both at the 
signal reception level and through inhibition of β-catenin transcriptional activity by 
binding Wnt3a via its sulfated GAG chains. In contrast, betaglycan’s chondroitin sulfate 
chains can promote Wnt3a signaling, suggesting that the composition of GAG chains 
may significantly alter cellular response to betaglycan and thereby Wnt signaling. 
Consistent with a lack of a role for betaglycan’s GAG chains in betaglycan’s functions as 
a TGF-β co-receptor (30), betaglycan’s suppression of canonical Wnt3a signaling is 
independent of TGF-β signaling and independent of betaglycan’s cytoplasmic domain 
interactions described previously (43,124,128). These results demonstrate an intricate 
mode of Wnt3a signaling regulation by betaglycan, mediated largely by its heparan and 
chondroitin chains, and lay the foundation to advance current understanding of the 
various roles proteoglycans, with different GAG chains, can have in maintaining cellular 
homeostasis, specifically through control of Wnt availability and signaling. 
2.2. Experimental Procedures 
Cell Lines and Reagents–Ovarian epithelial carcinoma cell lines SKOV3, and 
OVCA429 were obtained from Duke Gynecology/Oncology Bank (Durham, NC). 
Authentication of cell lines was carried out at the University of Colorado (Denver, CO) 
sequencing facility. Monkey kidney COS-7 (ATCC® CRL-1651™) cells, mouse 
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mammary tumor cell line 4T1 (ATCC® CRL2539™), normal Chinese hamster ovarian 
epithelial cell lines pgsA-745 (ATCC® CRL-2242™) and pgsD-677 (ATCC® CRL-
2244™) were obtained from ATCC (Manassas, VA). Epithelial carcinoma cell lines 
SKOV3, 4T1 and OVCA429 were cultured in RPMI-1640 (ATCC® 30-2001™) 
containing L-glutamine, 10% FBS, and 100 U of penicillin-streptomycin. COS-7 cells 
were maintained in DMEM (ATCC® 30-2002™) containing 10% FBS, and 100 U of 
penicillin-streptomycin. CHO cell lines pgsA-745 and pgsD-677 were cultured in 
Kaighn's Modification of Ham's F-12 Medium (ATCC® 30-2004™) containing L-
glutamine, 10% FBS, and 100 U of penicillin-streptomycin. All cells lines were 
maintained at 37°C in a humidified incubator at 5% CO2. Antibodies: phospho-LRP6 
(Ser1490) (#2568), LRP6 (#2560), β-catenin (D10A8) XP® Rabbit mAb (#8480), 
GAPDH Rabbit mAb (#14C10), HA Rabbit mAb (#3724) and Wnt3a (C64F2) Rabbit 
mAb (#2721) were from Cell Signaling Technology (Danvers, CA). Mouse E-cadherin 
mAb was purchased from BD Biosciences (#610181) (San Jose, CA). Human betaglycan 
Antibody (#AF-242-PB) was purchased from R&D Biosystems (Minneapolis, MN) and 
Actin (#A2228) from Sigma-Aldrich (St. Louis, MO). Mouse HA antibody (#32-6700) 
from Invitrogen (Carlsbad, CA). Inhibitor SB431542 hydrate (#S4317) was purchased 
from Sigma-Aldrich. Sodium chlorate (NaClO3) was obtained from Thomas Scientific 
(Swedesboro, NJ) and sodium sulfate anhydrous (Na2SO4) (#S421-500) from 
ThermoFisher Scientific (Waltham, MA). Heparinase III (#H8891) and Chondroitinase 
ABC (#C3667) were obtained from Sigma-Aldrich. Recombinant TGF-β1, TGF-β2 and 
Wnt3a were purchased from R&D Systems.  
Plasmid Constructs and Stable Cell Lines–Betaglycan constructs used in this 
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study have been described previously (9,86,89,129,130). Full length betaglycan consists 
of betaglycan/TβRIII-HA in pcDNA 3.1(+) as described previously (44,129). pcDNA 
3.1(+) betaglycan/TβRIII-ΔGAG construct consists of human betaglycan-HA, with 
serine-to-alanine point mutations at amino acids 534 and 545 to prevent GAG attachment 
(44,94,131,132). rTβRIII consists of the rat betaglycan sequence with HA tag in the 
pcDNA 3.1 vector (89). Adenoviral constructs were used at MOIs between 5-100 
particles/cell and infections performed as described previously (9,90,124).  shRNA 
sequences for betaglycan were obtained from Sigma-Aldrich with the following 
sequences: shRNA33430 (shTβRIII-1): 
CCGGCCAAGCATGAAGGAACCAAATCTCGAGATTTGGTTCCTTCATGCTTGGT
TTTTG and shRNA33432 (shTβRIII-2): 
CCGGCGTGCTTTATCTCTCCATATTCTCGAGAATATGGAGAGATAAAGCACGT
TTTTG in a pLKO.1-puro backbone (betaglycan shRNA construct and non-targeted 
control).  Lentiviral particles were generated at the Center for Targeted Therapeutics 
Core Facility and the University of South Carolina (Columbia, SC). For betaglycan 
knockdown, SKOV3 cells were infected with 1X betaglycan shRNA lentivirus.  Cells 
were then selected in the presence of 1 µg ml-1 puromycin. Stable cell lines were 
maintained in 0.5 µg ml-1 puromycin.  
Wnt3a-HA (#18030) and TβRII-ΔCyto (#14051) plasmids were purchased from 
Addgene (Cambridge, MA) (133). The soluble human betaglycan construct was a kind 
gift from Blobe, G. (Duke University, Durham, NC). Conditioned media containing 
soluble TβRIII/betaglycan was generated by transfecting cells with the indicated 
expression vectors, and were collected 48 h after transfection in serum-free conditions. 
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Transient DNA transfections were performed using Lipofectamine 2000 (#11668019) 
from Life Technologies (Carlsbad, CA) or FuGENE® 6 (#E2691) from Promega 
(Madison, WI) according to manufacturer’s instructions. Cell fractionation kit to analyze 
β-catenin localization came from Cell Signaling (#9038). Luciferase assay kit (#E1500) 
came from Promega and M50 Super 8x TOPFlash (134) used to measure luciferase 
activity was a gift from Randall Moon (Addgene plasmid #12456).  
Quantitative Polymerase Chain Reaction (qRT-PCR)–For qRT-PCR, total RNA 
was isolated from approximately 200K cells using Trizol reagent (Invitrogen). RNA was 
retro-transcribed using iScript™ Reverse Transcription Supermix (#1708841) and 
SsoAdvanced Universal SYBR Green Supermix (#1725271) from Bio-Rad (Hercules, 
CA). qRT-PCR primer sequences used were: RPL13A-F: AGATGGCGGAGGTGCAG, 
RPL13A-R: GGCCCAGCAGTACCTGTTTA, Betaglycan-F: 
CGTCAGGAGGCACACACTTA, Betaglycan-R: CACATTTGACAGACAGGGCAAT. 
Immunoprecipitation and Western Blotting–Immunoprecipitation and western 
blotting were performed using standard techniques as described previously (90,93,135). 
For co-immunoprecipitation in COS-7 cells, betaglycan-expressing cells were transfected 
with Wnt3a-HA construct indicated and culture media was collected 48 h after 
transfection in serum-free conditions. betaglycan was then immunoprecipitated by 
incubating the cell lysates overnight with anti-human betaglycan antibody. The next day, 
protein G–Sepharose beads were added to the lysates for 2 h at 4°C. The beads were then 
washed three times with cold phosphate buffer solution (PBS) and resuspended in sample 
buffer. The amount of betaglycan or Wnt3a bound to the beads was detected by western 
blot with anti-human betaglycan or Wnt3a antibodies.   
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Wnt3a-Betaglycan Pull-down Assay–This was performed as described previously 
(122,136). Briefly, OVCA429 cells were lysed in non-denaturing COIP lysis buffer (50 
mM TrisHCl, pH 7.5, 150 mM of NaCl, 1% Nonidet P-40, 10% glycerol, 1 mM DTT, 25 
mM NaF, 1 mM Na3VO4 and 1X protease inhibitor cocktail [#P8340, Sigma-Aldrich]). 
betaglycan-HA was then immunoprecipitated by incubating the cell lysates overnight 
with an anti-human betaglycan antibody. The next day, protein G–Sepharose beads were 
added to the lysates for 2 h at 4°C. Beads were then washed three times with PBS, and 
incubated with 20 nM Wnt3a-conditioned media for 2 h at 4°C. After two more washes 
with PBS, the beads were resuspended in sample buffer and the amount of Wnt3a bound 
to betaglycan was detected by western blot using anti-Wnt3a and anti-betaglycan 
antibodies.  
Luciferase Assay–Indicated cells were seeded in 24-well plates and were co-
transfected with a luciferase reporter vector containing a β-catenin-responsive promoter 
[to drive luciferase expression (TOPFlash, #12456, Addgene)] and SV40 (Renilla internal 
control vector). One day after transfection and infection, cells were incubated overnight 
with 50 ng ml-1 Wnt3a and then lysed. Luciferase activity (Luciferase Assay System, 
Promega) was measured by calculating the ratio between luciferase and Renilla activities 
(to normalize for transfection efficiency) and then normalizing values to the untreated 
sample.  
Immunofluorescence and Intensity Analysis–Indicated cells were seeded onto 
coverslips in 12-well plates at a density of 5x104 cells per well. After infections and 
treatment with 50 ng ml-1 Wnt3a, cells were washed with ice-cold PBS and fixed with 
100% methanol for 10 min followed by PBS washes. Cells were permeabilized with 
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0.1% Triton X-100 in PBS and then blocked with 3% BSA or 0.2% gelatin in PBS for 30 
min at room temperature, followed by an overnight incubation at 4°C with a rabbit anti-β-
catenin antibody. After extensively washing with PBS, cells were incubated with an 
Alexa-conjugated secondary antibody (Molecular Probes, Eugene, OR). Cells were 
mounted in mounting medium and analyzed under an Olympus IX81 motorized inverted 
microscope (Shinjuku, Tokyo, Japan). Fluorescence intensity for the β-catenin was 
analyzed using ImageJ 1.50d software (National Institutes of Health, USA) by drawing a 
fixed line of interest over the membrane and cytoplasm followed by averaging maximum 
intensities obtained from the plot profile plugin. To estimate the change in β-catenin 
localization after Wnt treatment, in the presence and absence of betaglycan, the ratio 
between membrane and cytoplasmic fraction of β-catenin fluorescence was calculated. 
Statistical significance of the data was analyzed in SigmaPlot version 11software. P-
values <0.05 were considered to be statistically significant. 
Subcellular Fractionation–Indicated cells were seeded in 12-well plates and 
infected to express betaglycan. 48 h post infection, cells were treated with 50 ng ml-1 
Wnt3a for 1 h and then lysed. Subcellular fractionation of β-catenin, cytoplasmic marker 
GAPDH and plasma membrane marker E-cadherin was carried out using the cell 
fractionation kit (Cell Signaling) according to manufacturer’s instructions. 
2.3. Betaglycan suppresses Wnt/β-catenin activity at the level of signal reception.  
  To investigate the role of betaglycan on signaling by Wnt glycoproteins, which 
have high affinities for both HSPGs and CSPGs (50,137,138), we expressed betaglycan 
in the ovarian cancer cell line OVCA429 that we, and others, have established express 
low levels of betaglycan (Figure 2.1A.i-ii) and (87,124)). Conversely, we reduced 
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expression of betaglycan by shRNA-mediated knockdown in the ovarian cancer cell line 
SKOV3, which express higher levels of betaglycan (Figure 2.1A.iii) and (139)). We 
examined whether betaglycan can affect canonical Wnt signaling as determined by 
phosphorylation of coreceptor LRP6, one of the first steps initiated by Wnts binding to 
their signaling coreceptors (140). We find that while Wnt3a robustly phosphorylated 
LRP6 at serine 1490 (141) in OVCA429 cells (low betaglycan levels), transiently 
increasing betaglycan expression in OVCA429 cells suppressed Wnt induced LRP6 
phosphorylation in a betaglycan dose dependent manner (Figure 2.1B). Total LRP6 levels 
remained stable in betaglycan-expressing OVCA429 cells when compared to OVCA429 
cells with low betaglycan levels (Figure 2.1B). In SKOV3 cells, which express high 
levels of betaglycan (Figure 2.1A.i), reducing betaglycan expression using shRNA 
resulted in increased LRP6 phosphorylation when compared to Wnt3a stimulated SKOV3 
control cells expressing high endogenous betaglycan (Figure 2.1C-D). To confirm that 
the effect of shBetaglycan was specific to betaglycan, we utilized shRNA resistant rat 
betaglycan (9,90) to rescue betaglycan expression and examined Wnt induced LRP6 
phosphorylation. We find that rescue of betaglycan expression in shBetaglycan cells 
(Figure 2.1A.iii) suppressed Wnt induced LRP6 phosphorylation compared to cells 
containing endogenous betaglycan (Figure 2.1C). Total LRP6 levels were not 
significantly altered by shRNA to betaglycan or transient expression of rat betaglycan in 
SKOV3 cells when compared to control cells (Figure 2.1C). Consistently, a second 
shRNA to betaglycan (shTβRIII-2) also resulted in increased LRP6 phosphorylation 
when compared to Wnt3a stimulated control cells  (Figure 2.1D). These results indicate 
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that betaglycan may regulate Wnt signaling at the signal reception level by suppressing 
canonical Wnt signaling.  
Activation of the canonical Wnt pathway leads to stabilization and accumulation 
of cytosolic β-catenin, which then enters the nucleus and regulates Wnt target genes 
(119). Consistent with reduced LRP6 phosphorylation, Wnt induced β-catenin cytosolic 
accumulation was significantly reduced in the presence of betaglycan (Figure 2.2A-B).  
Upon β-catenin accumulation and stabilization, activation of TCF/LEF-sensitive 
transcription by β-catenin provides a robust read-out of the Wnt-stimulated canonical 
pathway (142). To test if betaglycan-mediated changes on LRP6 phosphorylation and β-
catenin accumulation translated to downstream effects on TCF/LEF activity, we analyzed 
the activity of a TCF/LEF-sensitive reporter, which contains multiple β-catenin binding 
sites (134). We find that Wnt3a significantly increases TCF/LEF reporter activity in 
OVCA429 cells (Figure 2.2C). Increasing betaglycan expression in these cell lines 
resulted in a significant suppression of Wnt3a induced activation of the TCF/LEF-
reporter compared to control Wnt treated cells (Figure 2.2C). Similar to trends seen in 
OVCA429 cells, overexpressing betaglycan in SKOV3 cells (betaglycan–high) resulted 
in suppression of Wnt3a induced TCF/LEF activity compared to control Wnt treated cells 
(Figure 2.2C). Side-by-side analysis of Wnt3a stimulated TCF/LEF activity in SKOV3 
(high betaglycan) and OVCA429 (low betaglycan) cells in the same experiment revealed 
lower Wnt3a induced TCF/LEF activity in SKOV3 cells, when compared to Wnt3a 
treated ovarian cancer OVCA429 cells (Figure 2.2D), which we hypothesize is in part 
due to higher endogenous betaglycan expression in SKOV3 cells (Figure 2.1A, left 
graph). This hypothesis was confirmed in SKOV3 cells using shRNA to betaglycan 
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(Figure 2.1A, right graph) that resulted in enhanced Wnt induced TCF/LEF-reporter 
activity compared to control cells (Figure 2.2E). This increased Wnt signaling in 
shBetaglycan cells was suppressed upon restoring betaglycan expression using shRNA 
resistant rat betaglycan (Figure 2.2E), consistent with increased LRP6 activation 
observed in SKOV3 cells upon knockdown of betaglycan (Figure 2.1C). Regulation of 
TCF/LEF reporter activity by betaglycan was not restricted to ovarian cancer cells as 
betaglycan expression also repressed Wnt induced TCF/LEF reporter activity in 4T1 
(breast cancer) cells (Figure 2.4D), indicating broad impacts of betaglycan on Wnt 
signaling regulation. 
2.4. TGF-β signaling does not limit betaglycan’s ability to suppress Wnt/β-catenin 
signaling 
To begin elucidating the mechanisms by which betaglycan regulates Wnt 
signaling, we examined whether the presence of TGF-β a high affinity ligand for 
betaglycan’s core domain (143-145), impacted the ability of betaglycan to suppress Wnt 
signaling. We find that both TGF-β1 and TGF-β2 enhance Wnt induced LRP6 
phosphorylation and TCF/LEF activity (Figure 2.3A-B), in OVCA429 cells, but to a 
lesser extent in SKOV3 cells (high betaglycan) (Figure 2.3C, Lanes 1-4), indicating a 
cooperative role for TGF-β ligands in Wnt signaling that may be repressed by betaglycan. 
Treating betaglycan-knockdown SKOV3 cells (shTβRIII) with TGF-β resulted in an 
enhancement of the Wnt3a-TGF-β cooperativity, compared to control betaglycan-
expressing SKOV3 cells treated with Wnt3a and TGF-β (Figure 2.3C, Lanes 5-8). Since 
TGF-β2 binds the core domain of betaglycan with higher affinity than TGF-β1 (146) and 
showed the most robust enhancement of Wnt3a induced TCF/LEF activity (Figure 2.3A), 
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this ligand was chosen to determine TGF-β signaling mediated changes on suppression of 
Wnt3a induced TCF/LEF activity by betaglycan. We find that Wnt induced TCF/LEF 
activity, both in the absence and presence of TGF-β2, was dampened by betaglycan 
expression in OVCA429 cells (Figure 2.3D).  
To confirm that betaglycan does not require TGF-β signaling receptors to 
suppress Wnt signaling, we first utilized SB431542 (inhibitor of TβRI kinase activity) 
and analyzed Wnt induced TCF/LEF activity in OVCA429 cells. We find that inhibition 
of TβRI suppressed Wnt signaling independent of betaglycan expression in control cells 
(Figure 2.3E). However, inhibition of TβRI did not affect betaglycan’s ability to suppress 
Wnt induced TCF/LEF activity in OVCA429 cells when compared to control cells 
(Figure 2.3E) indicating that Wnt signaling repression by betaglycan is independent of 
TβRI kinase activity. Several TGF-β independent roles for betaglycan have been reported 
through its interactions with the Type II TGF-β receptor TβRII (143). However, transient 
expression of TβRII lacking its cytoplasmic domain (and therefore unable to interact with 
betaglycan) (TβRII–ΔCyto) (133,143), did not affect betaglycan’s ability to suppress Wnt 
induced TCF/LEF activity when compared to control cells (Figure 2.3F). Similar to 
Figure 2.3E, removal of TβRII’s cytoplasmic domain (TβRII–ΔCyto) in GFP-expressing 
cells led to a suppression of Wnt induced TCF/LEF activity when compared to control 
cells (Figure 2.3F). These betaglycan independent observations of TβRII–ΔCyto and 
SB431542 on TCF/LEF activity may point to autocrine TGF-β-Wnt signaling 
mechanisms unrelated to betaglycan’s ability to suppress Wnt dependent Wnt signaling. 
Collectively, these data suggest that even in the presence of the high affinity ligand TGF-
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β2, the absence of TGF-β signaling and betaglycan-TβRII interaction, betaglycan is still 
able to suppress Wnt signaling. 
2.5. GAG chains of betaglycan regulate Wnt signaling 
Wnt glycoproteins have been shown to have a high affinity for GAG chains on 
transmembrane proteoglycans (50) and the extracellular betaglycan domain contains two 
sites of HS and CS GAG chains (9,131). To determine if the chains on betaglycan are 
involved in the suppressive effects on Wnt signaling, we expressed either full-length 
betaglycan (TβRIII), betaglycan lacking GAG chain modifications (TβRIII-ΔGAG) (30) 
or control vectors in OVCA429 cells and assessed the levels of phosphorylation of LRP6, 
cytosolic β-catenin accumulation and TCF/LEF activity induced by exogenous Wnt3a. 
We find that, unlike full-length betaglycan, TβRIII-ΔGAG failed to suppress LRP6 
phosphorylation in OVCA429 cells (Figure 2.4A). Consistently, TβRIII-ΔGAG did not 
suppress Wnt3a-dependent β-catenin cytoplasmic accumulation compared to full-length 
betaglycan; instead, β-catenin cytoplasmic accumulation in the presence of TβRIII-
ΔGAG resembled cytoplasmic β-catenin levels observed in Wnt3a treated control cells 
(Figure 2.4B). TβRIII-ΔGAG cells also failed to suppress TCF/LEF activity when 
compared to full-length betaglycan (Figure 2.4C).  The effect of betaglycan’s GAG 
chains on Wnt signaling was not restricted to ovarian cells as TβRIII-ΔGAG also failed 
to suppress Wnt signaling when compared to full length betaglycan in the murine 
mammary 4T1 cells (Figure 2.4D).  
To test whether the extracellular domain (ECD) of betaglycan was sufficient to 
suppress Wnt induced signaling, we used two parallel approaches. We treated OVCA429 
cells, in the absence and presence of Wnt3a, with either conditioned media (CM) from 
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cells expressing only betaglycan’s ECD (Sol-TβRIII-1) (86,88,144) or CM from cells 
expressing full-length betaglycan containing soluble betaglycan in the media due to 
shedding (Sol-TβRIII-2) (30,144) (Figure 2.4E). CM from control vector (GFP) 
expressing cells was used as control (GFP-CM, Figure 2.4E). These conditions were 
compared to OVCA429 cells expressing full-length betaglycan in the same experiment 
(Figure 2.4E). We find that both shed and soluble forms of betaglycan were able to 
significantly suppress Wnt induced TCF/LEF activity to the same extent as expressing 
full-length betaglycan (Figure 2.4E). To control for possible artifacts associated with 
infection of vectors, we also tested media from uninfected cells (Figure 2.4F) and find 
that infection with GFP did not impact TCF/LEF activity (Figure 2.4F).  Taken together, 
these data confirm that betaglycan’s ECD and GAG chains are sufficient at suppressing 
Wnt induced signaling.  
2.6. Betaglycan interacts with Wnt and the balance between HS and CS chains 
determine betaglycan’s ability to regulate Wnt/β-catenin signaling 
To determine whether betaglycan binds Wnt3a, we used co-immunoprecipitation 
of recombinant Wnt3a and betaglycan, a methodology commonly used to study Wnt 
interactions with its receptors (122,136). We find a Wnt dose dependent interaction 
between betaglycan and Wnt3a in OVCA429 cells (Figure 2.5A). Consistent with the 
extracellular domain of betaglycan being sufficient to suppress Wnt signaling  (Fig. 4E), 
we find that soluble betaglycan was also able to interact with Wnt3a, as determined by 
using CM from COS-7 cells expressing full length betaglycan and HA tagged Wnt3a 
(Figure 2.5B). To determine if the betaglycan–Wnt3a interaction is mediated through 
betaglycan’s GAG chains as suggested by our Wnt signaling assays (Figure 2.4), we 
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incubated OVCA429 cell lysates with recombinant Wnt3a and performed co-
immunoprecipitation in cells expressing full-length betaglycan (TβRIII), TβRIII-ΔGAG 
or control (Experimental Procedures). We observed immunoprecipitation of Wnt3a and 
betaglycan that is reduced to background levels in cells expressing TβRIII-ΔGAG (Figure 
2.5C). These data indicate that the interaction/binding capacity of TβRIII-ΔGAG is 
significantly less than full-length betaglycan. These findings are consistent with TβRIII-
ΔGAG being unable to inhibit Wnt3a signaling (Figure 2.4B-C). 
Since betaglycan represses Wnt signaling and appears to interact with Wnt3a 
through its GAG chains, we aimed to test whether Wnt signaling regulation by 
betaglycan’s GAG chains are dependent on the sulfation state of betaglycan’s GAG 
chains. We treated betaglycan-expressing OVCA429 cells with sodium chlorate, a 
competitive inhibitor of ATP-sulfurylase, which results in proteoglycans arriving at the 
cell surface bearing nonsulfated heparan sulfate or chondroitin sulfate chains (147). We 
find that non-sulfated GAG chains on betaglycan significantly stimulated Wnt induced 
TCF/LEF activity (Figure 2.6A). Treatment with sodium sulfate, which overcomes the 
effects of sodium chlorate and restores sulfation of proteoglycans (147), decreased Wnt 
induced TCF/LEF activity compared to betaglycan-expressing OVCA429 cells only 
treated with sodium chlorate (Figure 2.6A). These results demonstrate that the sulfation 
of betaglycan’s GAG chains is required for betaglycan-mediated suppression of Wnt 
signaling and loss of sulfation results in increased Wnt induced signaling.  
Since the GAG chains on betaglycan comprise both HS and CS chains (127), we 
aimed to isolate the individual effects of the different GAG chains of betaglycan on Wnt 
signaling. To do this, we first determined whether betaglycan’s suppressive role in Wnt 
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signaling was conserved in parental Chinese Hamster Ovarian (CHO) K1 cells, where 
betaglycan expresses both HS and CS chains (148). Although CHO cells have a modest 
response to Wnt stimulation as observed previously (50,149) and by us (Figure 2.6B-C), 
we observed a significant decrease in Wnt signaling upon betaglycan-expression in CHO 
K1 cells compared to control cells (Figure 2.6B), consistent with our observations in 
ovarian and breast cancer cells (Figs. 2.2 and 2.4).  To determine the role of betaglycan’s 
CS chains in Wnt signaling, we utilized the CHO cell line derivative pgsD-677, which 
lack both N-acetylglucosaminyltransferase and glucuronyltransferase activities and are 
unable to synthesize heparan sulfate, but can produce high amounts of chondroitin sulfate 
(148). We increased betaglycan expression in pgsD-677 (ΔHS) cells (as described in 
Experimental Procedures) and examined Wnt induced TCF/LEF activity. Strikingly, we 
observed a significant increase in Wnt signaling, in betaglycan-expressing pgsD-677 cells 
compared to control cells (Figure 2.6C). Furthermore, removal of betaglycan’s CS chains 
with chondroitinase (Ch) (Figure 2.6D, right panel) reduced Wnt induced TCF/LEF 
activity in betaglycan-expressing pgsD-677 cells (Figure 2.6D). Since pgsD-677 cells 
express only CS GAG chains (148), we tested whether CS chains promote Wnt signaling 
in cells that made both HS and CS GAG chains. Similar to our results in pgsD-677 cells 
(Figure 2.6D), we find that betaglycan was able to further repress Wnt signaling in 
OVCA429 cells treated with chondroitinase as compared to control cells (2x repressed, 
Figure 2.6E). In contrast, heparanase (Hp) treatment of betaglycan-expressing OVCA429 
cells resulted in increased TCF/LEF activity compared to heparanase untreated cells (5x 
increased, Figure 2.6F). These data suggest that HS and CS chains on betaglycan 
contribute in an opposing fashion, to the availability of Wnt for signaling. Based on these 
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we propose that the HS chains of betaglycan are responsible for Wnt3a sequestration and 
subsequent betaglycan–mediated suppression of Wnt3a signaling.  In contrast 
betaglycan’s CS chains increase Wnt availability and signaling (Figure 2.6G).  
2.7. Discussion and Conclusions 
We provide novel evidence for TβRIII/Betaglycan-mediated regulation of 
canonical Wnt signaling through distinct functions of its HS and CS GAG chains. Our 
studies demonstrate that the HS chains of betaglycan are responsible for suppression of 
Wnt3a signaling, most likely via sequestering Wnt, in contrast with the CS chains of 
betaglycan, which promote Wnt signaling. Based on our findings, we propose that Wnt 
interactions with the HS chains on betaglycan result in sequestration of Wnt away from 
LRP6 and Frizzled, which decreases the levels of signaling-productive complexes 
between the ligand and its receptors. This hypothesis is confirmed upon examining the 
inability of betaglycan to suppress Wnt signaling upon removal of its GAG chains 
(Figure 2.4). Mechanistically, our pull-down assays in betaglycan-expressing cells 
(Figure 2.5) indicate interaction between betaglycan and Wnt glycoproteins, which have 
a high affinity for polyanionic compounds such as heparin (150), and reveal that the 
GAG chains significantly increase Wnt-betaglycan interaction to suppress Wnt signaling. 
Strikingly, betaglycan’s CS chains promote Wnt3a signaling in the absence of its HS 
chains (Figure 2.6B,D). To support this conclusion, chondroitinase treatment in pgsD-677 
and OVCA429 cells resulted in a loss of Wnt signaling, thus indicating an exciting new 
role for the chondroitin chains of betaglycan in stimulating Wnt signaling.  
 The role of GAG chains in Wnt signal transduction may also depend on the core 
protein and specific biochemical cues since our data indicate opposing functions for 
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betaglycan’s HS and CS chains in Wnt signaling. To support our hypothesis, it has been 
shown that exogenous chondroitin sulfate, heparin, and GAGs are unable to stimulate 
Wnt3a signaling while endogenous CSPGs promote Wnt signaling in mouse L cell 
fibroblasts, suggesting that the core proteins of CSPGs may be involved in regulating 
Wnt3a activity (137). We speculate that localization, sulfation and/or chain length of 
GAG chains attached to core proteins could contribute to differences in ligand 
availability and signaling.  
Studies have also shown that cell context can determine the role proteoglycans 
and GAG chains play in cancer progression. For instance, enzymatic elimination of 
chondroitin sulfate molecules in primary breast tumors, for example, increases lung 
metastases in mice (151) while digestion of cell surface CS on lung cancer cells injected 
into tail veins leads to a reduction in the number of tumor cells able to populate and 
metastasize (152). These results suggest that CS molecules may have opposing roles 
during cancer progression: an anti-metastatic function in primary tumor tissue and a pro-
metastatic role during extravasation (circulating cancer cell interaction with endothelial 
cells) (153). Other proteoglycans have also been shown to function as either tumor 
promoters or suppressors depending on the protein core, GAG chains attached, associated 
molecules, proteoglycan localization and tumor type (154). Perlecan, for example, can 
both promote tumor invasiveness (155) and inhibit angiogenesis (156) while glypicans 
and syndecans may promote local cancer cell growth and metastatic potential in some 
cancer tissues (138,157), but inhibit tissue growth, invasion and metastasis in others 
(158,159). Together, these data show a requirement for the proteoglycan’s core domain 
and cellular environment in deciding GAG chain function.   
 32 
In addition to the contributions made by the proteoglycan’s core domain and 
environment, the sulfation state of the proteoglycan also plays a major role in its ability to 
regulate signaling pathways. Upon treatment of our betaglycan-expressing OVCA429 
cells with sodium chlorate, an ATP-sulfurylase competitive inhibitor that causes 
proteoglycans to arrive at the cell surface bearing nonsulfated HS or CS chains (147), we 
find betaglycan unable to repress Wnt signaling, indicating that the sulfation of 
betaglycan’s GAG chains is required for proper Wnt signal regulation by betaglycan (Fig. 
6A), consistent with previous reports for Glypican-1 (50). Studies in Drosophila have 
also shown that, upon treatment of Drosophila cells with sodium chlorate or in the 
absence of an HS N-deacetylase/N-sulfotransferase, cells are completely deficient in HS 
chain sulfation and Wingless [Wg] signaling is disrupted (160-163). HS chain sulfation 
plays a vital role in regulating FGF signaling as well. Consistently, the HS chains of 
betaglycan can also regulate FGF signaling and play a critical role in tumor progression 
(9). 
Previous reports indicate that FGF signal transduction is dependent on sulfation of 
the 2-O and 6-O positions on HS chains, which control FGF1 binding to heparin and 
FGF1-dependent dimerization and activation of the FGFR1 receptor, respectively (164-
166). In articular cartilage, studies reveal a Wnt signaling promoter role for CS chains 
that is dependent on the sulfation of the CS chain (167). Taken together, these studies, 
combined with our data, suggest that sulfation plays a significant role in growth factor 
signaling regulation by GAG chains on proteoglycans.  
 It is possible that different expression levels of β1,4-N-
acetylgalactosaminyltransferase-I (β4GalNAcT-I) and/or α1,4-N- 
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acetylglucosaminyltransferase-I (α4GlcNAcT-I), which initiate the synthesis of CS or HS 
chains, respectively, may also contribute to betaglycan’s proteoglycan state and 
subsequent effects on Wnt signaling. Moreover, within a single core protein, Ser-Gly 
residues in a hydrophobic pocket might signal heparan sulfate attachment, while Ser-Gly 
residues in  an exposed hydrophilic environment might signal chondroitin sulfate 
attachment. These different local environments could achieve selectivity by modulating 
the activity of β4GalNAcT-I and α4GlcNAcT-I (168). Other biochemical cues may 
include the location of N-linked glycosylation sites (Asn-Phe-Ser) as described for 
Syndecan-1 (34). Attachment of an N-linked sugar at a GAG chain attachment site would 
likely prevent subsequent recognition by the xylosyltransferase and GAG chain 
attachment to betaglycan’s core protein. 
The precise mechanism by which CS chains of betaglycan increase Wnt 
availability remains to be determined. Future studies into the biochemical cues involved 
in determining the proteoglycan state of HSPGs, such as betaglycan, as well as 
betaglycan’s role in regulating Wnt signaling will help shed light on Wnt signaling 
regulation and increase our understanding of the diverse roles proteoglycans like 









               
 
Figure 2.1. TβRIII suppresses Wnt/β-catenin activity at the level of signal reception. 
(A) TβRIII mRNA expression by qRT-PCR analysis to detect (i) endogenous TβRIII 
levels in OVCA429 and SKOV3 cells, (ii) overexpression of TβRIII in OVCA429 cells 
as indicated and (iii) expression in SKOV3 cells of indicated shRNA and rescue 
conditions generated as described in Experimental Procedures. Ct values normalized in 
graph (i) to endogenous TβRIII levels in SKOV3 cells (lane 2), in graph (ii) to GFP (lane 
1) and in graph (iii) to Scr TβRIII levels (lane 1). Quantitations represent the average of 
two independent biological trials each conducted in triplicate. (B) OVCA429 cells 
transiently expressing increasing doses of TβRIII (5 & 10 MOI of TβRIII expressing 
adenoviral constructs) or control (GFP) were stimulated with 50 ng ml-1 Wnt3a for 1 h 
followed by immunoblotting of lysates for phospho-LRP6 (Ser1490) (pLRP6), LRP6, 
TβRIII and β-actin. (C) SKOV3 cells transiently expressing shRNA to TβRIII (shTβRIII-
1) or Scrambled (Scr) control (Experimental Procedures) and transiently transfected with 
rat TβRIII (rTβRIII) or control vector (pcDNA 3.1) for 24 h (for rescue of TβRIII 
expression as seen in 2.1A, right panel), and then stimulated with 50 ng ml-1 Wnt3a for 1 
h followed by immunoblotting of lysates for phospho-LRP6 (Ser1490) (pLRP6), LRP6 and 
β-actin. (D) SKOV3 cells transiently expressing a second, independent shRNA to TβRIII 
(shTβRIII) or Scrambled control (Experimental Procedures) were stimulated with 50 ng 
ml-1 Wnt3a for 1 h followed by immunoblotting of lysates for phospho-LRP6 (Ser1490) 
(pLRP6), LRP6 and β-actin. (B-D) Quantitations represent pLRP6: LRP6 ratios and are 
normalized to the untreated sample. All sub-figures (A-D) represent at least two 
independent biological trials. 
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Figure 2.2. TβRIII suppresses Wnt induced β-catenin cytoplasmic accumulation and 
transcriptional activity. (A) OVCA429 cells transiently expressing control (GFP) or 
TβRIII were stimulated with 50 ng ml-1 Wnt3a for 1 h and immunostained for β-catenin 
(red). Scale bars: 20 µm. Graph represents quantitation of β-catenin fluorescence at the 
membrane versus cytoplasm (Experimental Procedures). N ≥ 30 cells/condition. Values 
normalized to control GFP. Figure represents at least two independent biological trials. 
(B) Cytoplasmic fractions obtained after subcellular fractionation (Experimental 
Procedures) of OVCA429 cells transiently expressing TβRIII or GFP stimulated with 50 
ng ml-1 Wnt3a for 1 h followed by immunoblotting of lysates for β-catenin, GAPDH 
(positive cytoplasmic marker) and E-cadherin (negative cytoplasmic marker). Figure 
 36 
represents at least two independent biological trials. (C-E) Indicated cells expressing 
either TβRIII, shTβRIII, or shTβRIII with rTβRIII, as in Fig. 2.1B-C, were transfected 
with a Wnt-responsive luciferase reporter and SV40 control vector and left untreated or 
treated with 50 ng ml-1 Wnt3a for 24 h. Luciferase activity was then measured as 
described in Experimental Procedures. All values normalized to the untreated sample and 
represent the average of two independent biological trials each conducted in duplicate. 








Figure 2.3. TGF-β signaling does not limit TβRIII’s ability to suppress Wnt/β-
catenin signaling. (A) OVCA429 cells transfected with a Wnt-responsive luciferase 
reporter (500 ng) and a SV40 control vector were either untreated or stimulated with 50 
ng ml-1 Wnt3a and 400 pM TGF-β1 or TGF-β2 for 24 h. Luciferase activity was then 
measured as described in Experimental Procedures. (B) OVCA429 cells were either 
untreated or stimulated with 50 ng ml-1 Wnt3a and 400 pM TGF-β1 and TGF-β2 as 
indicated for 1 h. Cells were lysed and levels of phospho-LRP6 (Ser1490) (pLRP6) and β-
actin were assessed by immunoblotting. Quantitations represent pLRP6: LRP6 ratios and 
are normalized to the untreated sample. (C) SKOV3 cells stably expressing control or 
TβRIII shRNA-1 were either untreated or stimulated with 50 ng ml-1 Wnt3a and 400 pM 
TGF-β1 or TGF-β2 for 1 h. Cells were assessed as in 1B.	 Quantitations represent 
pLRP6:LRP6 ratios and are normalized to the untreated sample. (D-F) OVCA429 cells 
transiently expressing either control (GFP) or TβRIII were transfected with a Wnt-
responsive luciferase reporter and a SV40 control vector and incubated with (D) 50 ng ml-
1 Wnt3a in the presence or absence of 400 pM TGF-β2, (E) 50 ng ml-1 Wnt3a and 5 µM 
SB431542 or (F) 50 ng ml-1 Wnt3a and a dominant negative form of the Type II TGF-β 
receptor (TβRII-ΔCyto) or pcDNA 3.1 control vector for 24 h. Luciferase activity was 
measured as described in Experimental Procedures. Luciferase data are representative of 
at least two independent biological trials each conducted in duplicate. Data analyzed 
using two-tailed Student’s t-test and represent the mean±s.e.m. Western analysis data 
represent at least two independent biological trials. All values normalized to the untreated 
sample. 
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Figure 2.4. GAG chains of TβRIII suppress Wnt signaling. (A) OVCA429 cells 
transiently expressing full-length TβRIII, TβRIII-ΔGAG or GFP (control) were 
stimulated with 50 ng ml-1 Wnt3a. Cells were then lysed after 1 h and phospho-LRP6 
(Ser1490) (pLRP6), LRP6 and β-actin levels assessed by immunoblotting. Quantitations 
represent pLRP6:LRP6 ratios and are normalized to the untreated sample. (B) Indicated 
OVCA429 cells were stimulated with 50 ng ml-1 Wnt3a for 1 h and immunostained for β-
catenin (red). Scale bars: 20 µm. Graph represents quantitation of β-catenin fluorescence 
at the membrane versus cytoplasm (Experimental Procedures). N ≥ 30 cells/condition. 
Western analysis shows TβRIII and β-actin levels. Data analyzed using ANOVA 
followed by post hoc Shapiro-Wilk test and represent the mean±s.e.m. All values 
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normalized to the untreated sample. (C-F) Indicated cells were stimulated with either (C-
D) 50 ng ml-1 Wnt3a alone, (E) 50 ng ml-1 Wnt3a in the presence of either conditioned 
media (CM) from cells expressing only TβRIII-ECD (Sol-TβRIII-1), CM from cells 
expressing full-length TβRIII (Sol-TβRIII-2), or CM media from control GFP expressing 
cells for 24 h or (F) 50 ng ml-1 Wnt3a in the presence of control media from untransfected 
cells or from cells transiently expressing GFP. Cells were lysed after 24 h and luciferase 
activity measured in 1% serum as described in Experimental Procedures. All values 
normalized to the untreated sample. All luciferase data (C-F) are representative of at least 
two independent biological trials each conducted in duplicate. Data analyzed using two-
tailed Student’s t-test and represent the mean±s.e.m of a biological replicate. All values 
normalized to the untreated sample. All figures represent at least two independent 
biological trials.  
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Figure 2.5. TβRIII interacts with Wnt through its GAG chains. (A) OVCA429 cells 
transiently expressing full length TβRIII were immunoprecipitated and analyzed for 
Wnt3a-TβRIII interactions using the Wnt pull-down assay described in Experimental 
Procedures and previously in (122). All values normalized to the IgG sample. (B) 
Conditioned media from COS-7 cells transiently expressing full length TβRIII and 
Wnt3a-HA was immunoprecipitated using anti-TβRIII and immunoblotted using anti-HA 
and anti-TβRIII to analyze Wnt3a-TβRIII interactions as described in Experimental 
Procedures and previously in (90,93,135). (C) OVCA429 cells transiently expressing 
GFP (control), full length TβRIII or TβRIII-ΔGAG were immunoprecipitated using anti-
TβRIII and immunoblotted using anti-Wnt3a and anti-TβRIII to analyze Wnt3a-TβRIII 
interactions using the Wnt pull-down assay described in Experimental Procedures and 
previously in (122)  All values normalized to the GFP sample and all figures represent at 










Figure 2.6. The balance between sulfated heparan and chondroitin chains on TβRIII 
determines TβRIII’s ability to regulate Wnt/β-catenin signaling. (A) OVCA429 cells 
transiently expressing full length TβRIII, transfected with a Wnt-responsive luciferase 
reporter and a SV40 control vector were pre-treated with 50 mM NaClO3 with or without 
10 mM Na2SO4 as indicated for 2 h. Cells were then stimulated with 50 ng ml-1 Wnt3a and 
luciferase activity was measured as described in Experimental Procedures. All values 
normalized to the Wnt treated sample. (B-F) CHO K1, pgsD-677 or OVCA429 cells 
expressing TβRIII or GFP were transfected with a Wnt-responsive luciferase reporter and 
a SV40 control vector and pre-treated with (D-E) 100 mU ml-1 chondroitinase (Ch) or (F) 
20 mU ml-1 heparanase (Hp) for 2 h before overnight incubation with 50 ng ml-1 Wnt3a. 
Luciferase activity was measured as described in Experimental Procedures. All values 
normalized to the untreated sample. Western analysis in (D) shows TβRIII expression in 
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pgsD-677 cells after CS chain removal using 100 mU ml-1 chondroitinase. All data 
represent at least two independent biological trials. Data analyzed using two-tailed 
Student’s t-test and represent the mean±s.e.m. (G) Model of canonical Wnt/β-catenin 




GENERATION AND CHARACTERIZATION OF MODIFIED BETAGLYCAN AND 
SDC1 MUTANTS USING SITE DIRECTED MUTAGENESIS 
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3.1. Introduction 
Site-directed mutagenesis (SDM), a priceless tool used to modify DNA sequences 
for molecular biological studies and genetic engineering, is commonly used to study 
protein structure-function relationships with most mutagenesis methods based on PCR. 
To support the enzymatic digestion studies performed on full-length betaglycan (see 
Figure 2.6) and define new roles for SDC1’s individual GAG chains in cell signaling and 
cancer biology, we employed the simplest and most broadly applicable SDM protocol, 
the QuikChange
 
Site-Directed Mutagenesis System (QCM) (Stratagene, La Jolla, CA), 
and synthesized betaglycan and SDC1 mutants containing either CS or HS chains 
exclusively.  
The core domain of rat betaglycan contains six serine-glycine sequences of which 
only Ser535-Gly and Ser546-Gly are surrounded by the required acidic amino acids and 
tryptophan residue (Trp537) needed for GAG chain attachment (30,169-171). In humans, 
sequence alignment places these serines at the 534 and 545 amino acid positions ((9) and 
Figure 3.1).  Previously, using SDM, rat betaglycan containing serine-alanine mutations 
at serine 545 and serine 546 were expressed in monkey kidney fibroblast-like COS-1 
cells, affinity labeled with I-125TGFβ1, cross-linked with disuccinimidyl suberate (DSS) 
and labeled receptors were revealed by autoradiography. Mutation of either serine 
produced betaglycan forms of faster electrophoretic migration, causing an increase in 
GAG-less core protein expression (30). Double mutation of both serines completely 
abolished the addition of GAG chains while heparitinase and chondroitinase enzymatic 
digestions of these mutated betaglycan forms identified both HS (predominately) and CS 
chains at serine 535 and CS chains exclusively at serine 546 (30,170).  
In the case of SDC1, similar SDM of Ser-Gly sites followed by enzymatic 
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digestion via heparitinase and chondroitinase revealed three N-terminal cluster sites 
(DGSGD and FSGSGTG) for HS chain attachment (Ser37,45,47) and two C-terminal 
cluster sites (EGSGE and ETSGE) for CS chain attachment (Ser207, 217) in mice ((34,170) 
and Figure 3.2). Sequence alignment indicates human SDC1 contains two HS chain 
attachment sites (S45, 47) and three sites for CS chain attachment (S37,206,216). Analysis of 
betaglycan and SDC1’s HS and CS GAG chain composition and features are elaborated 
on in Section 1.1.ii.  
Using QCM, I introduced serine-to-alanine point mutations in betaglycan and 
SDC1, in a single PCR with one pair of complementary primers containing our mutation 
of interest, and generated the following betaglycan and SDC1 constructs: human 
betaglycan mutated at serine 545, which I have characterized to contain predominately 
HS chains (pcDNA3.1(+)-hBetaglycan-S545A-HA/TβRIII-S545A) (8.6kb), human 
betaglycan mutated at serine 534, which I have characterized to contain CS chains 
exclusively (pcDNA3.1(+)-hBetaglycan-S534A-HA/TβRIII-S534A) (8.6kb) and murine 
SDC1 mutated at serine 207 and 217 (pCMV2-mSDC1-ΔCS-Flag) (6.99kb). 
Characterization of this SDC1 mutant, to confirm the exclusive attachment of HS chains 
as described in (34,170), will be done in the future.  
After sequencing all new DMTP constructs (to verify successful SDM), I 
expressed these new DMTP forms in different cell types, enzymatically digested the 
GAG chains and then compared the results to human full-length betaglycan (pcDNA 
3.1(+)-hBetaglycan-FL-HA/TβRIII-FL-HA) (8.6kb), human betaglycan without GAG 
chains (pcDNA3.1(+)-hBetaglycan-ΔGAG-HA/TβRIII-ΔGAG-HA) (8.6kb), murine full-
length SDC1 (pCMV2-mSDC1-FL-Flag) (6.99kb), murine SDC1 with no HS chains 
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(pcDNA3-mSDC1-ΔHS) (6.99kb) and/or a GAG-less murine SDC1 (pcDNA3-mSDC1-
ΔGAG-Flag) (6.99kb) to confirm previously established (30,34,170) GAG chain 
attachment sites on betaglycan and SDC1. 
3.2. Experimental Procedures 
SDM Plasmid Construct Templates–Human betaglycan constructs used in this 
study have been described previously (9,86,89,129,130). Full-length betaglycan consists 
of human betaglycan-HA in pcDNA 3.1(+) (pcDNA3.1-hBetaglycan-HA) as described in 
(44,129,130). The pcDNA 3.1(+)-hBetaglycan-ΔGAG-HA construct consists of human 
betaglycan-HA, with serine-to-alanine point mutations at amino acids 534 and 545 to 
prevent GAG attachment (44,94,131,132). Full-length murine SDC1 construct, pCMV2-
mSDC1-Flag (#MG50641-M-F), was purchased Sino Biological (Beijing, China). Mouse 
pcDNA3-mSDC1-ΔGAG-Flag (69) contains serine-to-alanine point mutations at amino 
acids 37, 43, 45, 47, 207 and 217 to prevent GAG attachment while murine pcDNA3-
mSDC1-ΔHS (53) contains serine-to-alanine point mutations at 37, 45 and 47 to 
eliminate HS chain attachment. These SDC1 constructs were kind gifts from Sanderson, 
R. (University of Arkansas, Little Rock, Arkansas). Transient DNA transfections of these 
constructs were performed using Lipofectamine 3000 (#L3000008) from ThermoFisher 
Scientific (Waltham, MA) or FuGENE® 6 (#E2691) from Promega (Madison, WI) 
according to manufacturer’s instructions.  
Site Directed Mutagenesis-All primers designed to introduce the SDM were 
synthesized and purified by Integrated DNA Technologies (Coralville, IA). The PCR 
amplification was carried out with either QuikChange II XL Site-Directed Mutagenesis 
(Cat#200521, Agilent Technologies, Santa Clara, CA) (for pcDNA3.1(+)-hBetaglycan-
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S534A-HA), Q5® Site-Directed Mutagenesis Kit (Cat#E0554S, New England BioLabs, 
Ipswich, MA) (for pcDNA3.1(+)-hBetaglycan-S545A-HA) or QuikChange Lightning 
Multi Site-Directed Mutagenesis Kit (Cat#210515, Agilent Technologies) (for pCMV2-
mSDC1-ΔCS-Flag) per manufacturer’s instructions.  
Stable Cell Line Generation-To generate stable cells lines, each betaglycan 
construct was first cloned into an intermediate TOPO cloning vector and then into a 
pHIV-dTomato lentiviral backbone (Plasmid #21374, Addgene, Cambridge, MA) by the 
Center for Targeted Therapeutics Core Facility and the University of South Carolina 
(Columbia, SC). Lentiviral particles were then generated at the Center for Targeted 
Therapeutics Core Facility. Ovarian cancer line HEYA8 (gift from Murphy, S., 
University of South Carolina, Columbia, SC) monkey fibroblast kidney cell line COS-7 
(#CRL-1651, ATCC®) and human embryonic kidney cell line HEK293 (#CRL-1573, 
ATCC®) were infected with 1X betaglycan mutant lentivirus for 72 hr. HEYA8 cells 
were cultured in RPMI-1640 (ATCC® 30-2001™) containing L-glutamine, 10% FBS, 
and 100 U of penicillin-streptomycin. COS-7 and HEK293 cells were maintained in 
DMEM (ATCC® 30-2002™) containing 10% FBS, and 100 U of penicillin-
streptomycin. Cells were then sorted using flow cytometry at a cell density of 4 x 106/ml 
at the Center for Targeted Therapeutics Core Facility. Cell fractionation kit to analyze 
betaglycan localization came from Cell Signaling (#9038). For all primers, mutagenized 
positions are denoted in boldface and underlined. Reverse primers with a completely 
complementary role are marked with an asterisk. 
Quantitative Polymerase Chain Reaction (qRT-PCR)–For qRT-PCR, total RNA 
was isolated from approximately 200K cells using Trizol reagent (Invitrogen). RNA was 
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retro-transcribed using iScript™ Reverse Transcription Supermix (#1708841) and 
SsoAdvanced Universal SYBR Green Supermix (#1725271) from Bio-Rad (Hercules, 
CA). qRT-PCR primer sequences used were: RPL13A-F: AGATGGCGGAGGTGCAG, 
RPL13A-R: GGCCCAGCAGTACCTGTTTA, Betaglycan-F: 
CGTCAGGAGGCACACACTTA, Betaglycan-R: CACATTTGACAGACAGGGCAAT. 
Ovarian cancer lines not previously described include OVCAR5, OVCAR8, M41, 
OVCA420 and were obtained from the Duke Gynecology/Oncology Bank (Durham, 
NC). Authentication of cell lines was carried out at the University of Colorado (Denver, 
CO) sequencing facility. Cells were cultured in RPMI-1640 (ATCC® 30-2001™) 
containing L-glutamine, 10% FBS, and 100 U of penicillin-streptomycin.  
Immunoprecipitation and Western Blotting–Immunoprecipitation and western 
blotting were performed using standard techniques as described previously (90,93,135). 
Recombinant P. heparinus Heparinase III Protein (#6145-GH-010) was obtained from 
R&D Systems while Chondroitinase ABC (#C3667) was purchased from Sigma-Aldrich. 
For co-immunoprecipitation in betaglycan-expressing HEK293 cells, betaglycan was 
immunoprecipitated by incubating the cell lysates overnight with 6 µg of an anti-chicken 
Heparan Sulfate Proteoglycan antibody (#33 or 33-2-s, Developmental Studies 
Hybridoma Bank, Iowa City, IA). The next day, protein G–Sepharose beads were added 
to the lysates for 2 h at 4°C. The beads were then washed three times with cold phosphate 
buffer solution (PBS) and resuspended in sample buffer. The amount of betaglycan 
bound to the beads was detected by western blot with an anti-human betaglycan antibody 
(#AF-242-PB, R&D Biosystems).  
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3.3. Sequence and generation of DMTP constructs 
 For generation of pcDNA3.1(+)-hBetaglycan-S534A-HA, 50 µl PCR reaction 
was carried out with 100 ng template (pcDNA3.1(+)-hBetaglycan-ΔGAG-HA), 250 ng 
primer pair, 1 µl of Agilent dNTPs, 3 µl QuikSolution and 2.5 U PfuUltra HF DNA 
polymerase. The extension reaction was initiated by pre-heating the reaction mixture to 
95oC for 1 min; 18 cycles of 95oC for 50 sec, 60oC for 50 sec and 68oC for 1 min/kb of 
plasmid length; followed by incubation at 68oC for 7 min.  
To generate pcDNA3.1(+)-hBetaglycan-S545A-HA, 20 µl PCR reaction was 
carried out with 500 ng template (pcDNA3.1(+)-hBetaglycan-FL-HA), 2 µl 10 µM 
primer pair, 1 µl 10 mM dNTPs, 4 µl Q5 Buffer (Cat#E0554S, New England BioLabs) 
and 0.25 µl Q5 DNA polymerase (Cat#E0554S, New England BioLabs). The extension 
reaction was initiated by pre-heating the reaction mixture to 98oC for 3 min; 25 cycles of 
98oC for 1 min, 65oC, 70oC and 72oC for 30 sec and 72oC for 2.5 min/kb; followed by 
incubation at 72oC for 2 min. 
pCMV2-mSDC1-ΔCS-Flag, a murine SDC1 mutant with serine-to-alanine point 
mutations at amino acids 207 and 217 to prevent CS attachment, was generated using a 
25 µl PCR reaction containing 100 ng template (pCMV2-mSDC1-FL-Flag), 0.75 µl 
QuikSolution, 200 ng primer pair, 1 µl of Agilent dNTPs and 1 µl QuikChange Multi 
enzyme blend. The extension reaction was initiated by pre-heating the reaction mixture to 
95oC for 1 min; 30 cycles of 95oC for 1 min, 55oC for 1 min and 65oC for 2 min/kb of 
plasmid length according to the length of template; followed by incubation on ice for 2 
min to cool the reaction to ≤37°C.  
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PCR-amplified products were evaluated by agarose gel electrophoresis, purified 
by QIAquick PCR purification kit (Cat#28104, Qiagen, Germany) and further treated 
with restriction enzyme DpnI for 2 hr at 37oC. A 3 µl aliquot of each PCR product was 
transformed into XL10-Gold Ultracompetent cells and inoculated on Luria–Bertani (LB) 
plate containing 100 mg/ml ampicillin. A total of 10-12 colonies were selected and their 
plasmids were isolated by mini-prep. All plasmids were then sequenced by Eton 
Bioscience, Inc. (Research Triangle Park, NC) to identify positive mutants.  
3.4. Characterization of human betaglycan-S534A-HA and -S545A-HA 
To determine individual roles for betaglycan’s GAG chains in cell signaling and 
cancer, I used SDM to insert a serine-to-alanine point mutation at serine 534 in full-
length betaglycan or an alanine-to-serine point mutation at alanine 545 in hBetaglycan-
ΔGAG-HA to generate betaglycan containing either CS chains exclusively (hBetaglycan-
S534A-HA/TβRIII-S534A) or betaglycan containing predominately HS chains 
(hBetaglycan-S545A-HA/TβRIII-S545A) respectively (Figures 3.3 and 3.5A).  
PCR amplification of both hBetaglycan-S534A-HA and hBetaglycan-S545A-HA yielded 
satisfactory quantities of amplification products (Figure 3.5B) for cloning into an 
intermediate TOPO cloning vector. From the TOPO vector, these betaglycan mutants 
were cloned into a pHIV-dTomato lentiviral backbone for stable cell line generation and 
transient betaglycan expression analysis. 
To evaluate expression of the mutants, I transiently expressed betaglycan 
constructs pHIV-dTomato-hBetaglycan-FL-HA, -S534A-HA, -S545A-HA and -ΔGAG-
HA in both COS-7 and HEK293 cells (Figure 3.5C) and observed betaglycan core protein 
expression for all mutants with varying degrees of GAG chain expression. I also 
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performed betaglycan immunoprecipitation using a HSPG antibody in betaglycan-
expressing HEK293 cells and confirmed that betaglycan in HEK293 cells can express HS 
chains (Figure 3.5D). A similar immunoprecipitation in betaglycan expressing HEK293 
cells using a chondroitin sulfate proteoglycan antibody is warranted, as it would reveal 
whether CS chains attach to betaglycan in this cell line.  
To confirm that pHIV-dTomato-hBetaglycan-S534A-HA (TβRIII-S534A) 
expresses CS chains exclusively and to identify the GAG chains attached at serine 534 on 
pHIV-dTomato-hBetaglycan-S545A-HA (TβRIII-S545A) in cell lines, I first stably 
expressed these modified betaglycan constructs in COS-7 and HEYA8 cells (Figure 3.5F-
G). HEYA8 cells were identified as a low TβRIII-expressing ovarian cancer cell line 
based on qRT-PCR analysis of seven epithelial cell lines (Figure 3.5E). I then 
enzymatically digested the CS and HS chains on betaglycan using chondroitinase and 
heparitinase, respectively. In both COS-7 and HEYA8 cells, I find that treatment of 
hBetaglycan-S534A-HA with chondroitinase removed CS chains from betaglycan and 
increased betaglycan’s GAG-less core protein pools, indicating this modified form of 
betaglycan expresses only CS chains (Figure 3.5F). These results are thus consistent with 
prior reports on betaglycan’s GAG chain attachment sites (9,30,170). When hBetaglycan-
S545A-HA (TβRIII-S534A) expressing COS-7 and HEYA8 cells were treated with 
heparitinase alone, the majority of betaglycan’s GAG chains were removed, resulting in a 
large pool of betaglycan core protein with no GAG chains. When these same cells were 
treated with both chondroitinase and heparitinase, no reduction in GAG chain levels on 
hBetaglycan-S545A-HA was observed in COS-7 and only a slight reduction in GAG 
chain expression on HEYA8 hBetaglycan-S545A-HA was observed, indicating that 
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hBetaglycan-S545A-HA/TβRIII-S545A exclusively expresses HS chains in COS-7 cells 
and likely in HEYA8 cells (Figure 3.5G).   
To support my previously outlined (Figure 2.6) roles for betaglycan’s individual 
chains on Wnt signaling, I analyzed phospho-LRP6 and LRP6 basal levels in HEYA8 
cells lines stably expressing modified betaglycan forms. Compared to HEYA8 cells 
expressing full-length betaglycan, I observed an increase in both phosphorylated and total 
LRP6 levels in hBetaglycan-ΔGAG-expressing HEYA8 cells (TβRIII-ΔGAG)(Figure 
3.5H), consistent with our previous data (Figure 2.6). I also noticed an increase in total 
LRP6 levels in HEYA8 cells expressing hBetaglycan-S534A-HA/TβRIII-S534A (CS 
only betaglycan) compared to TβRIII-ΔGAG, with no change in phospo-LRP6 levels 
(Figure 3.5H). Between TβRIII-ΔGAG (no GAG chains), TβRIII-S534A (CS only 
chains) and TβRIII-S545A (Predominately HS chains), I find that, when HS chains are 
attached to betaglycan’s core, they reduce both LRP6 and phospho-LRP6 levels (Figure 
3.5H). Individual functions for betaglycan’s HS (TβRIII-S545A) and CS chains (TβRIII-
S534A)(Figure 3.5H) are consistent with our previous findings (Figure 2.6). Future 
studies to elucidate betaglycan’s individual GAG chain roles in Wnt signaling include 
identifying betaglycan’s GAG chain effects on β-catenin cytoplasmic 
accumulation/transcriptional activity and on soluble betaglycan pools, which have been 
shown to impact cell signaling/ligand availability (Sections 1.1iii, 2.5 and Appendix A).   
3.5. Characterization of pCMV2-mSDC1-ΔCS-Flag 
Using SDM, I inserted serine-to-alanine point mutations in mSDC1-FL-Flag 
construct at serines 207 and 217 to generate SDC1 containing CS chains exclusively 
(pCMV2-mSDC1-ΔCS-Flag) (Figures 3.2 and 3.6A). PCR amplification of pCMV2-
 53 
mSDC1-ΔCS-Flag produced a satisfactory amount of amplification product (Figure 3.6B) 
for sequence confirmation and transient expression analysis in HEK293 cells. While I 
observed SDC1 core protein and GAG chains for mSDC1-FL-Flag, mSDC1-ΔCS-Flag 
(Figure 3.6C) and mSDC1-ΔHS-His (Figure 3.6D), I could not confirm successful 
transfection of mSDC1-ΔGAG (data not shown), indicating further optimization of our 
transfection techniques is needed. Successful transient expression of all SDC1 constructs 
and modified SDC1 characterization, as performed for betaglycan, will lay a strong 
foundation for identification of new roles for DMTPs in cell biology.  
3.6. Conclusions 
 Here I outline generation and initial characterization of three new DMTP 
constructs, hBetaglycan-S534A-HA, hBetaglycan-S545A-HA and mSDC1-ΔCS-Flag. In 
combination with full-length and GAG-less DMTP forms, the modified forms of 
betaglycan are used in the following chapter to shed light on individual functions for HS 
and CS chains in cell signaling and cancer cell biology. Experiments conducted in 
Chapter 4 can also be performed using the modified forms of SDC1 to identify the broad 
impact of HS and CS chains on proteoglycans in regulating ligand availability and 
cellular responses.  
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Table 3.1. Primer sequences for SDM of Betaglycan and SDC1 




















































Figure 3.1. Human betaglycan-FL-HA amino acid sequence with indicated serines 
for HS (Serine 534 in red) or CS (Serine 545 in blue) GAG chain attachment in the 
pcDNA3.1(+) plasmid backbone. Serine-to-alanine point mutations were made at either 
(pcDNA3.1(+)- and pHIV-dTomato-hBetaglycan-S534A-HA and S545A-HA) or both 
(pcDNA3.1(+)- and pHIV-dTomato-hBetaglycan-ΔGAG-HA) serine residues to generate 
all hBetaglycan constructs. Green highlighted region indicates the amino acid sequence 























Figure 3.2. Mouse SDC1 amino acid sequence with indicated serines for HS (Serines 
37, 45, 47 in red) or CS (Serines 207 and 217 in blue) GAG chain attachment in the 
pCMV2 plasmid backbone. Serine-to-alanine point mutations were made at serine 













Figure 3.3. pcDNA3.1(+)-hBetaglycan-S534A-HA, -S545A-HA, ΔGAG-HA plasmid 
maps. Serine-to-alanine point mutations (indicated by white “A”) were introduced within 
the hBetaglycan-FL-HA construct at the indicated amino acid. hBetaglycan-FL-HA was 












Figure 3.4. pCMV2-mSDC1-ΔCS-Flag plasmid map. To generate pCMV2-mSDC1-
ΔCS-Flag, serine-to-alanine point mutations (indicated by white “A”) were introduced 
within the pCMV2-mSDC1-FL-Flag construct at amino acids 207 (AA 207) and 217 (AA 
217), the CS GAG chain attachment sites. 
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Figure 3.5. Characterization of human betaglycan-S534A-HA and -S545A-HA. (A) 
Serine-to-alanine point mutation at serine 534, serine 545 or both in human betaglycan 
for SDM of betaglycan containing either CS chains exclusively (hBetaglycan-S534A-
HA), betaglycan containing predominately HS chains (hBetaglycan-S545A-HA) or 
betaglycan containing no GAG chains (hTβRIII-ΔGAG-HA), respectively. (B) PCR 
amplification of both hBetaglycan-S534A-HA (lane 2) and hBetaglycan-S545A-HA (lane 
3) constructs. Lane 1 = DNA ladder, Lane 4 = QuikChange pWhitescript 4.5-kb Control. 
(C) Transient expression of 1 µg Empty (control) or betaglycan constructs pHIV-
dTomato-hBetaglycan-FL-HA, -S534A-HA, -S545A-HA and -ΔGAG-HA in both COS-7 
and HEK293 cells. Lysates were immunoblotted for TβRIII and β-actin. (D) Betaglycan 
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immunoprecipitation overnight with 6 µg of an anti-chicken Heparan Sulfate 
Proteoglycan antibody (#33 or 33-2-s, Developmental Studies Hybridoma Bank, Iowa 
City, IA) in betaglycan-expressing HEK293 cells. Lysates were immunoblotted for 
TβRIII and β-actin. (E) TβRIII mRNA expression by qRT-PCR analysis to detect 
endogenous TβRIII levels in seven ovarian cancer epithelial cell lines including HEYA8 
cells stably expressing hBetaglycan-FL-HA (HEYA8 TβRIII-FL-HA) (positive control). 
Quantitations represent the average of one independent biological trial conducted in 
triplicate. (F-G) Enzymatic digestion of betaglycan’s CS and HS chains using (F) 100 
mU ml-1 chondroitinase ABC from Proteus vulgaris (#C3667-5UN, Santa Cruz) (Ch) and 
50 ng ml-1 recombinant P. heparinus Heparinase III Protein (Hp) (R&D, #6145-GH-010) 
or (G) 100 mU ml-1 chondroitinase (Ch) alone for 2hr in both COS-7 and HEYA8 cells 
stably expressing the indicated hBetalgycan mutant. Lysates were immunoblotted for 
TβRIII and vincullin. (H) Western blot analysis of phospho-LRP6, LRP6 and Vincullin 





Figure 3.6. Characterization of pCMV2-mSDC1-ΔCS-Flag. (A) Serine-to-alanine 
point mutations at serines 37/45/47, serines 207/217 or all five serines in murine SDC1 
for SDM of SDC1 containing either CS chains exclusively (mSDC1-ΔHS), SDC1 
containing only HS chains (mSDC1-ΔCS) or SDC1 containing no GAG chains (mSDC1-
ΔGAG), respectively. (B) PCR amplification of mSDC1-ΔCS (lane 2). Lane 1 = DNA 
ladder. (C-D) Transient expression of 1 µg Empty (control) and mSDC1 constructs (C) 
pCMV2-mSDC1-FL and -ΔCS-Flag or (D) mSDC1-ΔHS-His in HEK293 cells. Lysates 
were immunoblotted for SDC1 (#sc-390791, Santa Cruz) and β-actin. 
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Tight control of growth factor/ligand availability at the cell surface is crucial to 
downstream signaling in both cancer and various other diseases/cell phenotypes(172-
174). Growth factors frequently utilized by cancer cells include, but are not limited to, 
FGF, Wingless (Wnt), BMP/GDF, Activin and TGF-β(9,33,87,100,113,138,175-185). 
These growth factors can interact with DMTPs to either promote or suppress signaling. 
One general mechanism for increasing signal reception is by concentrating ligands near 
their cognate signaling receptors to activate downstream signaling. Specifically, GAG 
chains on DMTPs could allosterically regulate and/or oligomerize soluble ligands, serve 
as guides for bringing growth factors and receptors into close proximity and/or provide 
proper alignment for productive binding to occur(186). In contrast, sequestering ligands 
away from their signaling receptors and/or disrupting receptor-receptor interactions could 
promote DMTP-mediated cell signal suppression. DMTPs could also serve as growth 
factor hubs, able to release growth factors at specific times for utilization by a subset of 
cells in a context dependent manner. 
By analyzing individual roles for HS and CS chains on DMTPs in growth factor 
signaling we can develop a framework to understand the biological impact DMTPs and 
their GAG chains have on ligand availability and signaling. Most importantly, this new 
knowledge could lead to the development of novel therapeutics to control cancer and 
other disease processes. Here, I identify new roles for betaglycan’s individual GAG 




4.1.i. Betaglycan Roles in TGF-β Signaling 
 To initiate signaling, TGF-β members, including BMP and Activin, interact with 
two types of receptors (type I and II) to transduce signals via the Smad family signal 
transducers(33,185,187,188). Upon ligand binding and receptor activation, the receptor 
complex phosphorylates the C-terminus of the receptor-regulated Smad proteins (R-
Smads, Smad1, 5 and 8 for BMP signaling and Smad2 and 3 for TGF-β signaling). 
Activated R-Smads then interact with the common partner Smad4 and accumulate in the 
nucleus, where the Smad complex directly binds defined elements on DNA and regulates 
target gene expression(33,185,187,188).  
Independent of its GAG chains(127), betaglycan’s ECD can bind all three TGF-β 
isoforms, BMP and Activin(33,189-191). Several studies suggest membrane betaglycan’s 
primary function in TGF-β signaling is to “present” ligands, such as TGF-β2, to the Type 
II TGF-β receptor to activate downstream signaling(187,191-193). In fibroblasts, for 
example, membrane betaglycan mediates TGF-β signaling by presenting ligands and 
trafficking the associated TGF-β receptors(187). This coreceptor role, however, does not 
fully encompass betaglycan’s impact on the TGF-β signaling pathway as sBetaglycan 
inhibits TGF-β signaling through ligand binding competition with membrane betaglycan 
in a variety of cell types (Figure 4.1 and (86,194,195)). Whether the impact of betaglycan 
in cancer is via direct TGF-β-mediated mechanisms has been poorly demonstrated/tested, 
as domain specific functions of betaglycan’s ECD in vivo have not been investigated in-
depth. However, upon loss of betaglycan, cancer cells do become less sensitive to TGF-β-
mediated cancer growth and migration, indicating that betaglycan can impact TGFβ-
dependent regulation of cancer cell behavior (Figure 4.1 and (193)). More recently, 
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betaglycan has been shown to tether TGF-β1 to the surface of cancer cell exosomes, 
which help cancer cells grow and spread as they drive TGF-β-induced differentiation of 
cancer-associated fibroblasts into myofibroblasts(196).  
To regulate BMP signaling, studies have shown that betaglycan’s core domain 
directly binds BMP2, although with lower affinity than TGF-β(33), and BMPs’ cognate 
receptors ALK3 and ALK6 (Figure 4.1 and (33)). Not only does betaglycan interact with 
BMP2, independent of its GAG chains(33), betaglycan’s core domain also directly binds 
BMP4, BMP7 and GDF-5 to enhance ligand binding to ALK3 and ALK6(33). This 
binding, in turn, promotes EMT of AV endothelial cells during development. In prostate 
cancer, betaglycan knockdown correlated with a significant decrease in BMP2 mediated 
Smad1 phosphorylation, indicating critical roles for betaglycan in facilitating BMP 
functions in both cancerous and non-cancerous cells(33).  
In addition to betaglycan’s ability to affect BMP induced cell biology through 
direct BMP binding, betaglycan’s core domain also impinges on BMP and TGF-
β/Activin signaling through high affinity core domain interactions with another TGF-β 
family member: Inhibin (Figure 4.1 and (189,197)). Upon binding Inhibin, betaglycan 
promotes Inhibin interactions with ActRII, ActRIIB and/or BMPRII type II 
receptors(189,198). This Inhibin-betaglycan-type II receptor complex leads to prevention 
of Activin and BMP induced type I-type II receptor interactions for 
signaling(189,198,199).  Since Inhibin binds with low affinity to type II receptors in the 
absence of betaglycan, the core domain of betaglycan plays a central role in potentiating 
Inhibin antagonism of Activin and BMP signaling (198,199). 
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4.1.ii. FGF Signaling and Betaglycan 
FGF glycoproteins, via their FGF receptors, regulate cancer cell proliferation, 
apoptosis, angiogenesis, EMT, motility and invasion and can also contribute to 
chemoresistance(174,200). The 18 members of the FGF family initiate their signaling 
cascade through four highly conserved transmembrane tyrosine kinase receptors 
(FGFR1-4). To access these receptors, secreted FGF ligands are released from ECM 
HSPGs, via heparinase and protease digestions(201,202), so that they can bind to FGFRs 
and cell surface HSPGs which aid in FGF receptor stabilization and downstream 
activation of multiple signaling pathways(201,203). In both neuroblastoma and 
osteoblasts, betaglycan’s HS chains are required for FGF activity (9,131). In 
neuroblastoma, betaglycan’s GAG chains bind FGF2 and FGFR1 to activate 
MAPK/ERK pathways and promote neuronal differentiation. This signal induction causes 
a significant decrease in neuroblastoma cell proliferation in vitro and tumor growth and 
metastasis in vivo, supporting betaglycan’s tumor suppressive role in cancer(9). 
4.2. Experimental Procedures  
Western Blotting–Western blotting was performed using standard techniques as 
described previously (90,93,135). All antibodies were obtained from Cell Signaling and 
include anti-rabbit phospho-p44/42/MAPK/Erk1/2 (#3179), anti-rabbit phospho-
SMAD1/5 (#9516), anti-rabbit SMAD1 (#6944) and anti-rabbit p44/42/MAPK/Erk1/2 
(#4695).  
Cell Viability Assay–Following stable expression of modified betaglycan in 
HEYA8 cells, the viability of HEYA8 cells was determined using MTT/Thiazoyl Blue 
Tetrazolium Bromide (#298-93-1, VWR, Radnor, PA), Briefly, 4K HEYA8 cells were 
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plated in a 96-well dish and incubated for 48 hr. Media was then removed and 10 µl of 5 
mg/ml MTT added to each well. Cells were incubated for 4 hr, MTT was removed and 
cells were resuspended in DMSO. Cell viability was measured at 570 nm with a 
microplate reader (Synergy H1 Hybrid Multi-Mode Reader, BioTek Instruments, Inc., 
Winooski, VT).  
Cell Growth Curves–HEYA8 cells (20K) were seeded into 12-well dishes. On the 
indicated day, cells were trypsinized and counted. Twelve measurements between two 
biologically independent wells/condition were counted averaged +/- SEM.  
Matrigel Invasion Analysis–Invasion assays were performed using 24-well 
transwells (Greiner Bio-One, Kremsmünster, Austria; ThinCertsTM, 24 well 8.0 µm) 
coated with 400 µg/ml MatriGel (BD Biosciences #3248404). Cells (20K) in serum free 
media were seeded in the upper chamber and allowed to invade for 24 hr toward serum 
media in the lower chamber. Filters were stained with Three Step Stain (Richard-Allan 
Scientific, San Diego, CA, USA). Filters were removed and mounted onto glass slides. 
Cells on the filter were counted using an Olympus DP21 microscope at x10 
magnification.  
4.3. Effect of betaglycan’s individual GAG chains on TGFβ superfamily and FGF 
signaling  
To determine roles for betaglycan’s individual GAG chains on TGFβ superfamily 
signaling, I have analyzed phosphorylated SMAD1/5 and total SMAD1 basal levels in 
our HEYA8 cells stably expressing our modified betaglycan forms. Compared to full-
length betaglycan, betaglycan-ΔGAG (TβRIII-ΔGAG) increases both phosphorylated and 
total SMAD1 levels (Figure 4.2A). When CS chains are added to betaglycan (TβRIII-
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ΔGAG versus TβRIII-S534A), phosphorylated SMAD1/5 levels increase while HS 
chains on betaglycan (TβRIII-S545A versus TβRIII-ΔGAG or TβRIII-S534A) suppress 
SMAD1/5 phosphorylation and reduce total SMAD1 levels (Figure 4.2A). These data 
indicate potentially opposing roles for betaglycan’s GAG chains in BMP signaling and 
lay the foundation for an in-depth analysis of betaglycan’s individual GAG chain effects 
on both BMP signaling (SMAD1/5) and TGFβ signaling (SMAD2/3) in the future.     
I have also initiated studies to determine the impact of betaglycan’s individual 
chains on basal FGF/ERK signaling in HEYA8 ovarian cancer cells. My preliminary 
findings indicate that hBetaglycan-S534A-HA (TβRIII-S534A) may suppress ERK 
phosphorylation (TβRIII-S534A versus TβRIII-ΔGAG) while the HS chains can enhance 
ERK phosphorylation (TβRIII-S545A versus TβRIII-S534A and in (9,100)) in our 
HEYA8 cells expressing modified betaglycan (Figure 4.2B).  
An in-depth study on individual functions for GAG chains on DMTPs, as they 
relate to FGF signaling and FGF-induced cancer cell biology in different cancer types, is 
warranted as it could reveal why DMTPs and sDMTPs exhibit both tumor-promoting and 
tumor-suppressive roles in FGF-mediated cancer progression.  
4.4. Impact of betaglycan’s individual GAG chains in regulating cancer cell 
behavior  
As outlined in Section 1.3, betaglycan is a crucial regulator of cancer progression 
with defined roles in apoptosis, adhesion, angiogenesis, proliferation, migration, invasion 
and metastasis in vitro and in vivo(2,9,39,52,86-96). As a strong predictor of overall and 
recurrence-free patient-survival in multiple cancers (86,90,100), it is crucial that we 
 69 
elucidate functions for betaglycan and its individual GAG chains in regulating key cancer 
phenotypes involved in averting current therapeutic strategies. 
To initiate these studies, we first analyzed modified betaglycan’s effects on 
HEYA8 ovarian cancer cell viability via a MTT assay. We find that betaglycan’s CS 
chains have no significant impact on HEYA8 cell viability (TβRIII-ΔGAG versus 
TβRIII-S534A). Betaglycan’s HS chains, however, reduce cell viability (TβRIII-S534A 
versus TβRIII-S545A), indicating a potential role for betaglycan’s HS chain in reducing 
ovarian cancer cell viability (Figure 4.2C). In line with this data, in both HEK293 and 
HEYA8 cells stably expressing modified forms of betaglycan, we find that betaglycan’s 
HS chains suppress cell proliferation (TβRIII-ΔGAG versus TβRIII-S534A) while the CS 
chains do not (TβRIII-ΔGAG versus TβRIII-S534A) (Figure 4.2D). To determine 
whether betaglycan’s individual chains alter ovarian cancer cell invasion, we performed a 
MatriGel invasion assay using betaglycan-expressing HEYA8 cells and find that 
attachment of CS chains to betaglycan’s core suppresses cancer cell invasion (TβRIII-
ΔGAG versus TβRIII-S534A) (Figure 4.2E) with no additional impact on invasion from 
betaglycan’s HS chains (Figure 4.2E).  
4.5. Conclusions 
Taken together, these data reveal unique, and at times opposing, roles for 
betaglycan’s HS and CS chains in cell signaling and biology. In BMP signaling, for 
example, HS-betaglycan (TβRIII-S545A) reduces SMAD1/5 phosphorylation while CS-
betaglycan (TβRIII-S534A) enhances SMAD1/5 phosphorylation. During FGF signaling, 
contrarily, TβRIII-S534A suppresses ERK phosphorylation while TβRIII-S545A 
enhances phosphorylation of ERK. Moreover, these opposing effects on signal 
transduction may contribute to the selectively of CS-betaglycan and HS-betaglycan in 
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controlling different cancer cell phenotypes. My bioassays revealed, for instance, that 
betaglycan’s HS chains reduced both ovarian cancer cell viability and proliferation with 
little to no contribution from betaglycan’s CS chains. However, CS-betaglycan, 
independent of betaglycan’s HS chains, were able to suppress cancer cell invasion, 
highlighting the importance of different chain types, on a single proteoglycan, in the 






Figure 4.1. DMTPs in growth factor signaling pathways. DMTPs betaglycan and 
SDC1 bind growth factors either through their GAG chains or core protein and then 
regulate ligand function through distinct mechanisms. Growth factors bound to 
membrane DMTPs are localized to the cell surface and are either presented to their 
associated signaling receptors (à) or sequestered away to prevent signal transduction (---
|). Additionally, soluble DMTP forms, generated by ectodomain shedding, bind ligands 
and either enhance or prevent signal complex formation. Abbreviations: BMP: Bone 
Morphogenetic Protein, BMPR: Bone Morphogenetic Protein Receptor, CS: Chondroitin 
Sulfate, ERK: Extracellular Signal-regulated Kinase, FGF: Fibroblast Growth Factor, 
FGFR: Fibroblast Growth Factor Receptor, FZD: Frizzled, GIPC: GAIP-interacting 
protein C terminus, HS: Heparan Sulfate, LRP6: LDL Receptor Related Protein 6, 
MAPK: Mitogen-activated protein kinase, sBetaglycan: Soluble/shed betaglycan, sSDC1: 
Soluble/shed SDC1, TGFβ: Transforming Growth Factor β, TβRI, RII: Transforming 

























Figure 4.2. Roles for betaglycan’s individual GAG chains in cell signaling and 
cancer cell behavior. HEK293 or HEYA8 (ovarian cancer) cells expressing the indicated 
TβRIII/Betaglycan mutant or Empty (control) were analyzed as follows: (A) Western blot 
analysis of phospho-SMAD1/5, total SMAD1/5, phospho-ERK1/2 and total ERK1/2 








































































































































103 cells plated in a 96-well dish and incubated for 48 hr. Cell viability was measured at 
570 nm with a microplate reader (Experimental Procedures). (C) Cell growth curves from 
2 x 104 cells for indicated number of days. Quantitations represent the average of two 
independent biological trials each conducted in sextuplet. (D) Transwell invasion through 
Matrigel measured after 24hr. All quantitative data analyzed using two-tailed Student’s t-









Much is known about the functions of SDC1 and betaglycan since their 
discoveries in 1989(34) and 1985(204) respectively, yet better definitions of the disease 
contexts in which the GAG chains on DMTPs are most relevant is required to improve 
our ability to use these DMTPs as diagnostic and prognostic markers and as biomarkers 
for treatment response. At the cell–ECM interface, betaglycan can control tumorigenic 
processes such as growth, invasion and metastasis by regulating growth factor availability 
through their GAG chain attachments. This dissertation work provides, for the first time, 
evidence of Wnt signaling regulation by TβRIII/Betaglycan through distinct functions of 
its HS and CS GAG chains. My biochemical studies demonstrate that HS-betaglycan 
(TβRIII-S545A) suppresses Wnt3a signaling, most likely via sequestering Wnt, while 
CS-betaglycan (TβRIII-S534A) promotes Wnt signaling in ovarian cancer cell lines. 
Mechanistically, pull-down assays in betaglycan-expressing cells (Figure 2.5) indicate 
interaction between betaglycan’s GAG chains and Wnt glycoproteins that likely lead to 
sequestration of Wnts away from their cognate receptors and subsequent Wnt signal 
suppression. To further characterize individual roles for betaglycan’s HS and CS chains 
in cancer biology, I employed an SDM protocol to generate human betaglycan mutants 
expressing either CS exclusively (hBetaglycan-S534A-HA) or predominately HS chains 
(hBetaglycan-S545A-HA) and confirmed GAG chain attachment via heparitinase and 
chondroitinase enzymatic digestions (Chapter 3). Using these betaglycan mutants, I have 
identified distinct roles for betaglycan’s HS and CS chains in both BMP and FGF 
signaling (Chapter 4) as well as in cancer cell biology in vitro, with HS-betaglycan 
capable of suppressing epithelial cell growth/viability and CS-betaglycan suppressing 
cancer cell invasion in vitro (Chapter 4).  
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 In addition to generating betaglycan mutants, I also generated a murine SDC1 
mutant containing only HS chains (mSDC1-ΔCS-Flag). In combination with full-length, 
CS only and GAG-less SDC1 forms, this SDC1-ΔCS-Flag construct can be used to 
determine whether betaglycan’s GAG chain effects on cell signaling and cancer biology 
are specific to betaglycan or signify broad roles for HS and CS chains on proteoglycans 
in regulating ligand availability and cellular responses. 
To further characterize individual, context-dependent roles for GAG chains on 
DMTPs in cell signaling and cancer biology, several biochemical assays can be 
employed. First, using radiolabeled growth factors (TGFβ, Inhibin, Wnt, BMP, FGF) and 
cross-linking and binding studies, roles for DMTP GAG chains in proteoglycan-ligand 
interactions could be determined. To evaluate the effects of DMTP GAG chains on 
DMTP shedding, which has been shown to impact cell signal transduction (Section 1.1.ii, 
2.5 and Figure A.1B), an ELISA could be performed with conditioned media (which 
contains soluble DMTPs) from cells expressing different DMTP forms (HS only, CS only 
or GAG-less). Additionally, to determine whether modifying GAG chains on betaglycan 
alters cell surface expression and intracellular localization, which can also impact cell 
signaling responses, subcellular fractionation or immunofluorescent analysis could be 
performed. These localization studies would also aid in delineating receptor/ligand 
trafficking/internalization mechanisms related to changes in DMTP GAG chain 
expression. Taken together, these studies would add to current knowledge on individual 
roles for GAG chains on a single core protein in regulating key biological phenotypes and 
cell signaling pathways responsible for promoting aberrant cell behavior and disease 
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Appendix Results and Discussion 
This appendix includes supportive data for betaglycan roles in epithelial cell 
signaling and biology.  
Figure A.1A. Betaglycan reduces TCF/LEF activity in IGROV ovarian 
cancer cells. Both SKOV3 (Figure 2.1A, left graph) and IGROV ovarian carcinoma 
epithelial cells express higher endogenous betaglycan levels, compared to other ovarian 
cancer cell lines (i.e. OVCA429). As such, to determine whether higher betaglycan levels 
in IGROV cells contribute to reduced Wnt signaling, as observed in SKOV3 cells (Figure 
2.2C), I used shRNA to betaglycan and measured TCF/LEF activity in these cells. I find 
enhanced basal and Wnt induced TCF/LEF-reporter activity in shBetaglycan IGROV 
cells, compared to control cells (Figure A.1A), supporting observations that betaglycan 
is, in part, responsible for the reduced TCF/LEF activity in cells with higher endogenous 
betaglycan (Figure 2.2C). 
Figure A.1B. Soluble CS-betaglycan enhances LRP6 phosphorylation. To 
support CS-betaglycan’s role in enhancing Wnt-induced TCF/LEF activity in OVCA429 
cells (Figure 2.6 and 3.5H), I analyzed LRP6 phosphorylation in both HEK293 and 
OVCA429 cells after stimulation with Wnt3a and in the presence of conditioned media 
(sGFP/sTβRIII-FL/sTβRIII-ΔGAG) from CHO pgsD-677 cells (express CS GAG 
chains only). I observed an increase in LRP6 phosphorylation in the presence of soluble 
CS-betaglycan compared to control cells or cells expressing GAG-less betaglycan (Figure 
A.1B), supporting the previously established Wnt signaling promoter role for CS-
betaglycan in Wnt signaling (Figures 2.6D-E and 3.5H). 
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Figure A.1C. Betaglycan’s GAG chains differentially affect Wnt target genes. 
In HEYA8 ovarian cancer cells, modified forms of betaglycan were stably expressed 
(Chapter 3) to analyze the individual roles betaglycan’s HS and CS chains play in 
regulating cellular signaling events. To determine whether betaglycan’s individual GAG 
chains alter Wnt target gene mRNA expression, qRT-PCR analysis of common Wnt 
target genes axin2, c-myc and ccnd1 was performed in both HEK293 cells (confirmation 
of transient betaglycan GAG chain expression awaiting enzymatic digestion analysis), 
and HEYA8 ovarian cancer cells. I observed no significant change in basal Wnt target 
gene mRNA expression upon addition of CS chains to betaglycan’s core domain (TβRIII-
ΔGAG vs. TβRIII-S534A) with the exception of a slight increase in axin2 mRNA 
expression in HEK293 cells (Figure A.1C). Interestingly, I observed an increase in basal 
mRNA expression levels for the majority of Wnt target genes upon addition of HS chains 
(TβRIII-S534A vs. TβRIII-S545A) to betaglycan’s core (Figure A.1C), indicating that 
betaglycan’s HS chains may promote transcription of certain Wnt target genes in certain 
cellular contexts. Further analysis of Wnt target gene activation by betaglycan’s 
posttranslational modifications is warranted to fully elicit the impact of DMTPs on Wnt 
target gene activity.    
Figure A.1D. GAG chains on betaglycan alter Frizzled1-betaglycan 
interactions. To identify a potential mechanism for betaglycan’s suppressive effects on 
Wnt signaling activity, I performed a betaglycan-Frizzled (Fzd) proximity ligation assay 
in OVCA429 cells expressing either full-length betaglycan (TβRIII-FL) or GAG-less 
betaglycan (TβRIII-ΔGAG) (Figure A.1D). Compared to control cells, I observed a 
decrease in Fzd-betaglycan proximity upon Wnt3a treatment (Figure A.1D), supporting a 
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mechanism that allows betaglycan to sequester Wnt3a away from Fzd in order to reduce 
signal activation. Moreover, upon removal of betaglycan’s GAG chains, I observed no 
decrease in betaglycan-Fzd proximity after Wnt3a stimulation, indicating betaglycan’s 
GAG chains play a direct role in regulating Fzd-betaglycan proximity. 
Figure A.1E. Betaglycan suppresses Wnt5a signaling in bladder cancer. In 
addition to betaglycan’s roles in suppressing Wnt3a signaling, betaglycan is also able to 
suppress Wnt5a signaling. J82 bladder cancer cells expressing full-length betaglycan 
were unable to induce JNK phosphorylation to the same extent as control cells treated 
with Wnt5a in a time-dependent manner (Figure A.1E). These data (Figure A.1E and 
Chapter 2) indicate that betaglycan is capable of suppressing multiple hyperactive Wnt 
signaling cascades in epithelial cells.  
Figure A.1F. Betaglycan interacts with Wnt5a. To determine a potential 
mechanism for betaglycan’s suppressive effects on Wnt5a signaling, I performed co-
immunoprecipitation analysis (see Chapter 2 Methods) in COS-7 cells transiently 
expressing full-length betaglycan and murine Wnt5a (MG50154-NF, Sino Biologicals). I 
observed betaglycan-Wnt5a interactions (Figure A.1F), which could potentially reduce 
Wnt5a signaling (as observed in Figure A.1E) if betaglycan sequesters Wnt5a from its 
receptors.  
 





Figure A.1. Additional roles for betaglycan in Wnt signaling. (A) Indicated cells 
expressing either NTC (control) or shTβRIII were transfected with a Wnt-responsive 
luciferase reporter and SV40 control vector and left untreated or treated with 50 ng ml-1 
Wnt3a for 24 h. Luciferase activity was then measured as described in Experimental 
Procedures. All values normalized to the untreated sample and represent the average of 
two independent biological trials each conducted in duplicate. Data analyzed using two-
tailed Student’s t-test and represent the mean±s.e.m. (B) Indicated cells were stimulated 
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CHO pgsD-677 cells expressing either TβRIII with CS chains exclusively (sTβRIII-FL), 
GAG-less TβRIII or GFP for 24 h (sGFP). Right CHO pgsD-677 graphs indicate Tβ
RIII expression levels in these cells. Lysates were immunoblotted for phospho-LRP6, 
TβRIII and β-actin. (C) qRT-PCR analysis was performed in HEK293 and HEYA8 
(ovarian cancer) cells expressing the indicated TβRIII/Betaglycan mutant or Empty 
(control) to detect mRNA expression of Wnt target genes axin2, c-myc and cyclin-D. 
Quantitations represent the average of one independent biological trial conducted in 
triplicate. Data analyzed using two-tailed Student’s t-test and represent the mean±s.e.m. 
(D) Fluorescent images of proximity ligation in OVCA429 ovarian cancer cells between 
full length TβRIII or TβRIII-ΔGAG with endogenous Frizzled1 (Fzd1), with or without 1 
h 50 ng ml-1 Wnt3a treatment. Quantification of the interaction compared with control 
cells is presented. N ≥ 50 cells/condition. (E) Western analysis of 50 ng ml-1 Wnt5a 
treatment at indicated times in J82 bladder cancer cells. Lysates were immunoblotted for 
phospho-JNK (#9255, Cell Signal), TβRIII and β-actin. (F) COS-7 cells transiently 
expressing full length TβRIII and murine Wnt5a-HA (mWnt5a-HA) were 
immunoprecipitated using anti-TβRIII and immunoblotted using anti-Wnt5a (#2530, Cell 
Signal) and anti-TβRIII to analyze Wnt5a-TβRIII interactions as described for Wnt3a in 




Figure A.2. Betaglycan’s GAG chains differentially affect TGFβ superfamily 
target genes and MMP mRNA expression. To determine roles for betaglycan’s GAG 
chains on growth factor target genes, I performed qRT-PCR in HEYA8 and HEK293 
cells expressing modified forms of betaglycan and analyzed mRNA expression for TGFβ 
(ID1) and BMP (PAI1) target genes (Figure A.2A-B). Additionally, I analyzed mRNA 
levels for MMPs, which cleave betaglycan and release sBetaglycan into the extracellular 
environment (See Section 1.1.iii). In normal HEK293 epithelial cells, betaglycan’s CS 
chains enhanced both ID1 and PAI1 mRNA expression (Figure A.2A-B, TβRIII-ΔGAG 
vs. TβRIII-S534A). In HEYA8 ovarian cancer epithelial cells, however, CS-betaglycan 
suppressed ID1 and PAI1 mRNA expression (Figure A.2A-B, TβRIII-ΔGAG vs. TβRIII-
S534A), indicating opposing roles for CS-betaglycan in normal versus cancerous 
epithelial cells. Contrasting functions for HS-betaglycan were also observed in normal 
HEK293 cells versus cancerous HEYA8 cells. Compared to TβRIII-S534A (CS-
betaglycan), betaglycan’s HS chains decreased ID1 expression in HEK293 cells but 
enhanced ID1 mRNA expression in HEYA8 cells (Figure A.2A, TβRIII-S534A vs. 
TβRIII-S545A). A slight decrease in PAI1 mRNA expression was observed upon 
addition of HS chains to betaglycan’s core domain in HEK293 cells (Figure A.2B, 
HEK293 TβRIII-S534A vs. TβRIII-S545A) while in HEYA8 ovarian cancer cells, 
adding HS chains to betaglycan significantly enhanced PAI1 mRNA expression (Figure 
A.2B, HEYA8 TβRIII-S534A vs. TβRIII-S545A). These data support unique and 
opposite roles for betaglycan’s individual GAG chains in normal versus cancerous 




Analysis of MMP expression in HEK293 cells, upon addition of CS chains to 
betaglycan, revealed a significant increase in MMP10 mRNA levels but a decrease in 
MMP3 mRNA expression (Figure A.2C, TβRIII-ΔGAG vs. TβRIII-S534A), indicating 
differences in MMP target gene regulation by CS-betaglycan.  I observed no significant 
effect on MMP mRNA expression upon attachment of HS chains to betaglycan (Figure 
A.2C, TβRIII-S534A vs. TβRIII-S545A), indicating HS chains on betaglycan do not 
affect MMP mRNA expression in normal epithelial cells. In HEYA8 cells, CS-
betaglycan did not alter MMP3 or MMP10 mRNA expression while HS-betaglycan only 
increased MMP10 mRNA levels (Figure A.2C, TβRIII-S534A vs. TβRIII-S545A), 
indicating minor contributions from betaglycan’s GAG chains on MMP3 and MMP10 
expression/activity. Analysis of other MMPs may reveal new functions for DMTP GAG 






Figure A.2. Betaglycan alters matrix metalloproteinases (MMPs) and TGFβ 
superfamily target gene mRNA. qRT-PCR analysis was performed in HEK293 and 
HEYA8 (ovarian cancer) cells expressing the indicated TβRIII/Betaglycan mutant or 
Empty (control) to detect: (A) ID1 (BMP target gene) mRNA expression, (B) PAI1 
(TGFβ target gene) mRNA expression or (C) MMP3 and MMP10 mRNA expression. 
Quantitations represent the average of one independent biological trial conducted in 
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